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Abstract
TAR-DNA-binding protein 43 (TDP-43) misfolding and aggregation is a major pathological
hallmark of frontotemporal dementia-amyotrophic lateral sclerosis (FTD/ALS). FTD/ALS is
characterized by motor and cognitive impairment, with cognitive impairment frequently reported
before the onset of classical motor symptoms. Yet, treatment for cognitive decline in FTD/ALS
is lacking, and robust cognitive phenotypes related to TDP-43 proteinopathy have not been
established for most mouse models of FTD/ALS. Herein, we used automated touchscreen
technology to assess executive function (affected in FTD/ALS) in male TDP-43Q331Klow and G348C

FTD/ALS transgenic mice. The touchscreen pairwise visual discrimination task revealed

impairments in 4-5-month-old TDP-43Q331Klow and -G348C mutants during acquisition and reversal
phases. These cognitive impairments manifested prior to motor symptoms. This pattern of results
is highly similar to observations in human FTD/ALS. Together, these findings identify the
combination of TDP-43 mouse models and touchscreen tests as potentially useful tools for
understanding and developing cognitive therapies in FTD/ALS.

Keywords:
TDP-43, ALS, FTD, BPSD, touchscreen, cognition, mouse, executive function,
neurodegenerative disease
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Summary for Laypersons
Amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD) are interconnected and
incurable progressive neurodegenerative diseases. ALS is characterized by brain and spinal cord
neuronal death leading to loss of control over voluntary movement, consistently resulting in
paralysis. Eventually, respiratory failure ensues from involuntary muscles becoming affected
(e.g., diaphragm), with patients succumbing to the disease within 3-5 years. Those afflicted by
FTD experience cognitive dysfunction (e.g., attention and memory), which negatively impacts
their personality and social and professional behaviours. The cause of FTD is unknown;
however, in 45% of cases functional alterations of a protein called TDP-43 is detected during
autopsies. Intriguingly, aggregated TDP-43 is detected in 95% of ALS cases, irrespective of
mutations related to ALS. Furthermore, ALS symptoms (e.g., motor impairments) are detected in
FTD (~15%), and FTD symptoms (e.g., cognitive impairments), are frequently detected in ALS
(~60-70%). Moreover, cognitive impairment is often reported before detection of motor
dysfunction symptoms in ALS. Replicating key human FTD/ALS features in TDP-43 mouse
models is essential for understanding and developing treatments for FTD/ALS. We explored
whether we could detect cognitive alterations and/or motor impairments caused by the insertion
of human TDP-43 protein into mice. We utilized a touchscreen system adapted for mice, which
allows us to assess cognition in mice in the same way as in humans, facilitating cross-species
comparisons. During testing we observed FTD/ALS-like cognitive deficits in TDP-43 mutant
mice, consistent with cognitive deficits prominent in human FTD/ALS. Furthermore, the
cognitive deficits observed in TDP-43 mutant mice manifested before the onset of any motor
impairments related to FTD/ALS. Together these findings suggest that the TDP-43 mutant mice
are able to recapitulate some key features of human FTD/ALS, showing that such models may be
very useful for the development of cognitive therapies and drug treatments for human FTD/ALS.
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1. Introduction
1.1 General Introduction
Amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease, is a lateonset rapidly progressive and incurable neurodegenerative disease, which features deterioration
of motor neurons of the nervous system (Gao et al., 2018; J. R. Mann et al., 2019). The
degeneration of motor neurons leads to muscle denervation, muscle atrophy and an eventual
inability to initiate voluntary movement (Gao et al., 2018; Ling et al., 2013). Intriguingly, ALS
frequently presents with symptoms of fronto-temporal dementia (FTD), another
neurodegenerative disease.
FTD is the second most prevalent form of dementia following Alzheimer’s disease (AD; Young
et al., 2018). FTD is a consequence of fronto-temporal lobar degeneration (FTLD), a specific
pattern of cortical neurodegeneration with distinct molecular signatures (Gao et al., 2018;
Heyburn & Moussa, 2017; Ling et al., 2013), which is a key neuropathological feature linking
FTD and ALS (Arnold et al., 2013a; Gao et al., 2018; Harrison & Shorter, 2017). FTD with
FTLD is accompanied by prominent behavioural and personality changes in addition to cognitive
deficits (Harrison & Shorter, 2017; Heyburn & Moussa, 2017; Ling et al., 2013). Patients with
ALS presenting with cognitive deficits experience significantly worsened disease progression,
which hastens terminal endpoints (Elamin et al., 2011; Giordana et al., 2011). FTD-related
cognitive dysfunction is present in ~60-70% of ALS cases. Moreover, ~15% of FTD cases are
complicated by motor deficits which meet the criteria for an ALS diagnosis (Elamin et al., 2011;
Giordana et al., 2011; Ling et al., 2013; Woolley & Strong, 2015).

The trans-active response element DNA-binding protein (TARDBP; gene) 43 (TDP-43) is one of
the main proteins implicated in ALS (Heyburn & Moussa, 2017). Among TDP-43
proteinopathies, TDP-43 nuclear clearance, cytosolic aggregation, detergent-resistant aggregate
formation and hyperphosphorylated and ubiquitinated forms are pathological hallmarks (Gao et
al., 2018; Heyburn & Moussa, 2017; Ling et al., 2013). Causative or FTD/ALS-linked mutations
in TARDBP can produce TDP-43 proteinopathy, and TDP-43 proteinopathy not linked to
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mutations can result in FTD/ALS. Additionally, TDP-43 positive inclusions have been detected
in ~45 percent of FTLD cases (Banks et al., 2008; Gao et al., 2018; Ling et al., 2013). In this
study the cognitive alterations resulting from FTD/ALS-linked TDP-43Q331K and TDP-43G348C
mutations will be investigated in transgenic mouse models of FTD/ALS.

1.2 Amyotrophic Lateral Sclerosis
ALS is a rapidly progressing neurodegenerative disease characterized by a variety of canonical
biological alterations related to the degeneration of motor neurons. Specifically, the upper motor
neurons which descend from the brain and innervate the spinal cord degenerate and the lower
motor neurons and their axons innervating skeletal muscle degenerate as well (Banks et al.,
2008; Gao et al., 2018; Heyburn & Moussa, 2017). The progressive degeneration of these
neurons can manifest in two different varieties early in the ALS disease time course. ALS
patients can be afflicted by spinal-onset ALS (~80% of cases) producing substantial loss of limb
strength, or alternatively, a bulbar-onset ALS(~20% of cases) producing dysphagia (struggling to
swallow) and dysarthria (struggling to speak; Hardiman, 2010). Regardless of which type of
ALS manifests, the resultant neurodegeneration invariably causes paralysis and death within a
period of 3 – 5 years following diagnosis (Banks et al., 2008; Gao et al., 2018).

ALS is the most common form of motor neuron disease (Heyburn & Moussa, 2017). The onset
of ALS is often around age 55, and invariably results in paralysis and death, usually 3 – 5 years
following diagnosis (Banks et al., 2008; Chen et al., 2013). Nonetheless, there is quite large
amount of heterogeneity amongst ALS related symptoms, time of onset, and progression of the
disease (Banks et al., 2008; Chen et al., 2013; Chiò et al., 2018; Hardiman, 2010). Globally, the
incidence of ALS is approximately 2 new diagnoses of ALS for every 100,000 people each year
(statistic is equivalent in Canada), and between 2500 – 3000 people age 18 and above are
currently living with the disease in Canada (Chen et al., 2013). Sex differences have also
frequently been observed, with males being at a higher risk of ALS. Reports indicate that the
male to female ratio ranges between 1 and 2 (Longinetti & Fang, 2019). Some risk factors have
also been established for ALS, namely, smoking, intense physical activity and diesel exhaust
fume exposure (Longinetti & Fang, 2019).
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ALS is predominantly sporadic with ~90% of cases lacking a familial link. The outstanding
~10% are familial ALS (fALS ; familial history of inherited ALS with a causative mutation)
cases with inherited mutations causative for ALS (Chen et al., 2013). The most prevalent of these
mutations is C9ORF72 which represents ~40% of all fALS cases, followed by SOD1 (~12%),
TARDBP (~4-5%), and FUS (~4-5%; Chen et al., 2013; Heyburn & Moussa, 2017). The
remaining proportion of cases are represented by UBQLN2, sequestosome 1, optineurin, profilin
1, valosin-containing protein, senataxin and potentially other yet to be identified genes (Chen et
al., 2013; Heyburn & Moussa, 2017).

Indeed, a comprehensive understanding of the pathogenesis of ALS has not yet been established,
despite the clinicopathological framework of ALS first being described in the mid 19 th century
and the first causative mutation being discovered in the early 1990s (Mathis et al., 2019). The
multifaceted nature of ALS increases the difficulty in identifying the exact mechanism(s)
producing degeneration (Gao et al., 2019), and several complementary mechanisms have been
proposed. The misfolding and aggregation of various proteins (e.g., FUS, SOD1 & TDP-43,
discussed below) within diseased neurons and glia is one such mechanism, and is thought to
induce neurotoxicity and degeneration (Gao et al., 2018; Heyburn & Moussa, 2017; Ling et al.,
2013). Glutamate toxicity is another potential mechanism of toxicity, which is suggested to play
a role in ALS neurodegeneration (Heyburn & Moussa, 2017). TDP-43, one of the key proteins
involved in pathological changes in ALS, processes the RNA of genes encoding synaptic
proteins such as glutamate transporters and receptors (Giribaldi et al., 2013; Heyburn & Moussa,
2017). Specifically, excitatory amino acid transporter-2 has been shown to be downregulated in
ALS, suggesting the possibility of reduced glutamate uptake in ALS, and an excess of glutamate
in the extracellular space causing excitotoxicity (Heyburn & Moussa, 2017). Oxidative stress and
reactive oxygen species are also mechanisms known to contribute to FTD/ALS
neurodegeneration (Gao et al., 2018; Ling et al., 2013).

Interestingly, cognitive impairment has recently become recognized as an integral component in
ALS pathology, with data supporting a strong correlation between ALS and cognitive disorders
(Ferrari et al., 2011; Gao et al., 2018; Heyburn & Moussa, 2017). ALS patients frequently
present with frontotemporal dysfunction leading to cognitive dysfunction afflicting roughly 60 –
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70% of ALS patients, even in the absence of any genetic mutations related to FTD/ALS (Elamin
et al., 2011; Olney et al., 2005; Woolley & Strong, 2015). Moreover, the development of
cognitive impairments significantly worsens the outcomes of ALS patients, when compared with
ALS patients who do not exhibit cognitive impairments. Indeed, there is an approximately 30%
reduction in survival outcomes for ALS patients with cognitive impairment following diagnosis
(Elamin et al., 2011; Giordana et al., 2011; Olney et al., 2005). Executive function deficits -- an
assortment of higher cognitive processes regulating mnemonic functions, which rely on
attention, reasoning, planning and cognitive flexibility -- are the most pronounced cognitive
aspects dysregulated in ALS disease pathology (Barber et al., 1995; Barulli et al., 2015; Kasper
et al., 2015; Machts et al., 2014; Mantovan et al., 2003; Rabinovici & Miller, 2010; Watermeyer
et al., 2015).

1.3 Fronto-Temporal Dementia and Fronto-Temporal Lobar Degeneration
FTD is a heterogenous neurodegenerative disease, which is clinically diagnosed based on various
phenotypical alterations to temperament and cognition (Harrison & Shorter, 2017). Overall, there
are approximately 1 – 17 cases of FTD per 100,000 people globally. Narrowing the scope to
individuals 70 years of age or greater brings the range to 1 – 4 cases per 100,000 people. Global
prevalence of FTD ranges between 2 – 31 cases per 100,000 people. A number of factors can
increase the risk of FTD development; for example traumatic head injuries were found to
contribute to a 3.3-fold increase in associated risk for developing FTD, and thyroid disease
contributes to a 2.5 fold increase (Onyike & Diehl-Schmid, 2013). It is currently unclear whether
there are sex difference associated risks for FTD due to contrasting reports (Chambers et al.,
2016; Hogan et al., 2016; Onyike & Diehl-Schmid, 2013).

The aetiology of FTD is strongly linked to genetic factors, with familial mutations representing
~40% of cases (D. M. A. Mann & Snowden, 2017). Furthermore, sporadic and familial FTD
presentations are linked to specific clinical phenotypes I will describe later (Van Mossevelde et
al., 2018). Three mutations are currently recognized as causative for FTD. Namely,
hexanucleotide repeat expansion mutations in C9ORF72, mutations in MAPT, and GRN
mutations driving TDP-43 pathology (D. M. A. Mann & Snowden, 2017). FUS is also implicated
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in FTD, though its presentation is predominantly sporadic and when mutated is associated with
ALS. Other less frequent mutations have also been identified such as UBQLN2, valosin
containing protein, optineurin and TANK binding-kinase 1 (D. M. A. Mann & Snowden, 2017).

Interestingly, although FTD and ALS are quite distinct with regards to their disease progression,
they are linked through a shared neuropathological feature, namely, FTLD (Banks et al., 2008;
Heyburn & Moussa, 2017; Young et al., 2018). FTLD pathology is the underlying cause of FTD,
which is clinically diagnosed through observed cognitive alterations and imaging techniques
(Erkkinen et al., 2018; Heyburn & Moussa, 2017; I. R. Mackenzie & Neumann, 2017; Young et
al., 2018).

1.4 FTD and FTLD Presentation Variations
FTLD pathology is typically observed in the frontal and temporal lobes, insular cortex and
orbitofrontal cortices (Erkkinen et al., 2018; Heyburn & Moussa, 2017; Hofmann et al., 2019; J.
R. Mann et al., 2019). The severity of FTLD progression and subsequent cognitive impairment
can vary from mild to a fast-progressive degeneration, which can manifest prior to the onset of
canonical ALS motor symptoms (Lomen-Hoerth et al., 2003; Strong et al., 2003). FTLD can be
identified histopathologically in post-mortem tissue based on the signature of aggregated
proteins (Heyburn & Moussa, 2017; Hofmann et al., 2019; D. M. A. Mann & Snowden, 2017).
Typical presentations of FTLD manifest as one of three distinct molecular derivates based on
aggregated proteins, such as FTLD-FUS, FTLD-Tau and FTLD-TDP, all of which can be
identified neuropathologically to show accumulation of the specific protein (FUS, Tau and TDP43, respectively; Gao et al., 2018; Hofmann et al., 2019; Sleegers et al., 2010). The first FTLD
derivative to be identified was Tau (Hofmann et al., 2019; Sleegers et al., 2010), a microtubulebinding protein involved in many neurodegenerative diseases. FTLD-Tau disrupts microtubule
stability, and axonal transport (Sleegers et al., 2010). FTLD-Tau is frequently observed in
patients with Pick’s disease (a FTD variant with Tau accumulation), although familial FTD
patients with mutations on the MAPT gene can also exhibit tau pathology representing
approximately 35 – 45% of FTLD cases. FTLD-FUS represents roughly 5 – 10% of FTLD cases.
FUS is a RNA-binding protein regulating RNA complexes in the nucleus among other functions
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(Heyburn & Moussa, 2017; Hofmann et al., 2019; Sleegers et al., 2010). Perturbed FUS
trafficking can produce a loss of function or gain of toxicity, though it is not known which
specific mechanism ultimately leads to the loss of cell viability. Furthermore, FTLD-FUS does
not exhibit the same pattern of pathology observed in FTLD-TDP despite belonging to the same
RNA-binding protein family. This suggests perhaps that there is a different mechanism and or
pathway that produces degeneration in these cases (Sleegers et al., 2010). The majority of FTLD
cases are of the TDP variant, with approximately 45 – 60% of post-mortem analyses showing
immunoreactivity to ubiquitin with TDP-43 being the primary constituent of the inclusions
(Hofmann et al., 2019; Sleegers et al., 2010)

FTD can be categorized based on symptoms and typically presents in one of three variants.
Namely, behavioural variant FTD (variant of interest herein), and two language variants,
semantic dementia and primary non-fluent aphasia. Presentations of behavioural variant FTD are
1.5 – 3 times more common than the semantic dementia and primary non-fluent aphasia variants
(Erkkinen et al., 2018; Heyburn & Moussa, 2017; Hofmann et al., 2019). Characteristically,
semantic dementia is rarely familial, though reliably linked to TDP-43 pathology and presents
with bilateral atrophy (often asymmetrically biased) of the temporal lobes diminishing the ability
to comprehend language (Heyburn & Moussa, 2017; D. M. A. Mann & Snowden, 2017).
Primary non-fluent aphasia is characterized by asymmetric degeneration of the left cortical
hemisphere inducing speech production deficits and is linked to TDP-43 pathology (Heyburn &
Moussa, 2017; D. M. A. Mann & Snowden, 2017). Behavioural variant FTD presentations are
most frequently familial, strongly associated with TDP-43 pathology and demonstrate frontal and
anterior temporal lobe atrophy (Heyburn & Moussa, 2017; D. M. A. Mann & Snowden, 2017).
Behavioural variant FTD is diagnosed based on the degree of alterations to compulsivity and or
perseveration, empathy, social behaviour and altered dietary patterns (Erkkinen et al., 2018;
Heyburn & Moussa, 2017; Young et al., 2018). Importantly, these behavioural variant FTD
features are not characteristic of typical AD, and parsing out these clinical phenotypes in patients
facilitates the differentiation between AD and FTD ensuring timely diagnoses (Erkkinen et al.,
2018; Heyburn & Moussa, 2017; Young et al., 2018). There are also atypical FTD variants that
present with Parkinson’s disease (PD)/ Parkinsonian-related disorders, motor neuron disease, and
or limb apraxia (Hogan et al., 2016; Onyike & Diehl-Schmid, 2013). Nevertheless, the
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identification of FTD variants is confirmed through post-mortem analyses of FTLD pathological
protein signatures (Heyburn & Moussa, 2017; Young et al., 2018).

1.5 FTD Clinical Identification
Briefly mentioned previously, FTD variants can be identified with some success through clinical
approaches. However, evidence of, behavioural and or cognitive deterioration must be observed
by a clinician or reliable caretaker before an evaluation for possible FTD is permitted. Possible
FTD can then be diagnosed should at least three of the following criteria as defined by the
International Behavioural Variant FTD Criteria Consortium be met: (a) early behavioural
disinhibition (e.g., impulsivity and deterioration of social etiquette/behaviour); (b) early loss of
sympathy and or empathy; (c) early apathy; (d) early perseverative and or compulsive like
behaviour; (e) hyperorality and alterations to diet; (f) demonstrated deficits of executive function
with largely unaltered visuospatial faculties and episodic memory (Rascovsky et al., 2011;
Young et al., 2018). Collectively, these behaviour and cognitive characteristics are often referred
to as behavioural and psychological symptoms of dementia (BPSD; Erkkinen et al., 2018; Tible
et al., 2017; Young et al., 2018). Probable FTD cases would satisfy the possible FTD conditions
and would fall into the probable category if verified by neuroimaging (e.g., magnetic resonance
imaging, computerized tomography & positron emission tomography), and showing some
evidence of FTLD pathology (Young et al., 2018). Definitive FTD can be diagnosed after
meeting the possible FTD criteria, but additionally must demonstrate either evidence of FTLD
pathology (via brain biopsy or autopsy), or a verified pathogenic mutation (Erkkinen et al., 2018;
Rascovsky et al., 2011; Young et al., 2018).

Due to the heterogenous nature of FTD and its mostly psychopathological manifestations,
misdiagnosing FTD as a psychiatric or other neurodegenerative disorder is possible; especially in
the early stages of disease progression (Erkkinen et al., 2018; Young et al., 2018). Bipolar
disorder, schizophrenia, depression and obsessive compulsive disorder are just a selection of
possible misdiagnoses which can occur in up to 50% of cases (Erkkinen et al., 2018).
Furthermore, AD can also complicate FTD diagnoses; however a combination of clinical
phenotypes and imaging techniques can increase the accuracy of an FTD diagnosis (Erkkinen et
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al., 2018; Hansson et al., 2019). Mentioned previously, FTD is diagnosed based on a collection
of cognitive alterations, namely, a dysexecutive neuropsychological profile and relatively intact
memory and visuospatial performance, features that are not typical of AD (Erkkinen et al., 2018;
Heyburn & Moussa, 2017; Young et al., 2018). AD patients do, however, frequently exhibit
mesial temporal and posterior atrophy, which is not characteristic of FTD, and can be revealed
by structural magnetic resonance imaging. Differentiation is also possible using positron
emission tomography with amyloid binding tracer techniques (Erkkinen et al., 2018). Moreover,
a non-imaging technique that is not reliant on phenotypical FTD cognitive alterations is
cerebrospinal fluid (CSF) collection. CSF assessment can reveal the ratio of amyloid beta42/40
which is used as a biomarker for AD to distinguish AD from mild cognitive impairment and
other dementias (Erkkinen et al., 2018; Hansson et al., 2019).

1.6 FTD/ALS Exist on a Single Spectrum
The relatively frequent co-occurrence of FTD and ALS has led to the neurodegenerative diseases
being recognized to exist on a single clincopathological spectrum, with etiological, pathological
and genetic commonalities (Erkkinen et al., 2018; Gao et al., 2018; Hofmann et al., 2019;
Ringholz et al., 2005; Sleegers et al., 2010; Van Langenhove et al., 2012). Cognitive dysfunction
has also been substantiated as a critical component of ALS. This is supported by neuroimaging
investigations illustrating that up to 50% of ALS patients lacking overt dementia demonstrate
mild atrophy of the frontal lobe, comparable to anatomical and morphological alterations present
in FTD (Lomen-Hoerth et al., 2003; Massman et al., 1996; Talbot et al., 1995). Ultimately, up to
70% of ALS cases are complicated by FTD (Ling et al., 2013; Strong et al., 2003; Woolley &
Strong, 2015). Confounding of FTD cases by ALS has also been highlighted, with ~15% of FTD
cases exhibiting ALS motor deficits (Ling et al., 2013). Additional evidence of an FTD/ALS link
stems from spinal cord post-mortem analysis of FTD patients (infrequently examined) revealing
cytoplasmic inclusions exhibiting immunoreactivity to ubiquitin in ~25% of cases (I. R. A.
Mackenzie, 2007; I. R. A. Mackenzie & H. Feldman, 2005). Ubiquitinated inclusions are a
hallmark of TDP-43 proteinopathy in ALS, and the colocalization of TDP-43 and ubiquitin is
rare in other neurodegenerative diseases (Gao et al., 2018; I. R. A. Mackenzie, 2007; Young et
al., 2018). Based on the collective discourse surrounding FTD/ALS reviewed thus far, the
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putative understanding of FTD/ALS changed to acknowledge their existence on a single
clincopathological spectrum, with the two diseases presenting etiological, pathological, genetic
and clinical convergences (Gao et al., 2018; Heyburn & Moussa, 2017; Ling et al., 2013).
Nevertheless, a more comprehensive understanding of the precise pathomechanisms by which
TDP-43 proteinopathy, FTD/ALS related mutations and cognitive dysfunction contribute to
motor- and neuro-degeneration is desperately needed.

1.7 FTD/ALS Genetic Mutations
Characteristically, FTD and ALS are heterogenous diseases which can arise sporadically, or from
various gene mutations that have been identified as causative or increase the risk of developing
FTD/ALS (Chen et al., 2013; Hofmann et al., 2019). There are many FTD/ALS related
mutations (in excess of 50), with a few commonly researched ones such as, chromosome 9 open
reading frame 72 (C9ORF72), fused in sarcoma (FUS), ubiquilin-2 (UBQLN2), superoxide
dismutase 1 (SOD1) and TDP-43 (TARDBP; Gao et al., 2018; J. R. Mann et al., 2019). A
multitude of distinct pathological alterations can be produced by these mutations, such as
neuroinflammation, RNA instability, protein aggregation and misfolding, oxidative stress,
irregular axonal transport and excitotoxicity (Gao et al., 2018; Picher-Martel et al., 2019; Renton
et al., 2014).

SOD1 is a cytoplasmic protein involved in the mitigation of oxidative stress, through the
detoxification of superoxide radicals (Chen et al., 2013). SOD1 was also the first causative ALS
gene to be discovered, though those afflicted by this mutation present with peculiarities when
contrasted with classical ALS symptomatology (Chen et al., 2013; Heyburn & Moussa, 2017;
Renton et al., 2014). The most notable contrasts observed in SOD1 patients are an extended
disease time course, the rarity of cognitive dysfunction and the rarity of detection in sALS cases
(Picher-Martel et al., 2019; Renton et al., 2014). The specific processes enabling SOD1
mutations to produce ALS pathology are currently unknown (Chen et al., 2013). Additionally,
the SOD1 mutation represents only a small proportion of ALS patients, and does not exhibit the
FUS or TDP-43 pathology observed in most ALS cases. Consequently, questions have been
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raised regarding the role of SOD1 in ALS, and whether it is unique among other ALS variants
(Chen et al., 2013; Heyburn & Moussa, 2017; Picher-Martel et al., 2019; Renton et al., 2014).

The FTD/ALS-linked protein FUS (sometimes referred to a translocated in liposarcoma; TLS) is
a member of the heterogeneous ribonucleoprotein particle family of which TDP-43 also belongs
(Chen et al., 2013; Harrison & Shorter, 2017). Similarly to TDP-43, the putative function of FUS
is RNA metabolism; it also possesses an intrinsically disordered low-complexity domain
rendering it prone to aggregation, and further, is capable of undergoing liquid-liquid phase
separation (Chen et al., 2013; Harrison & Shorter, 2017; Hofmann et al., 2019). More
specifically, FUS is involved in the nucleocytoplasmic trafficking of RNA, processing of
microRNA and long-intronic sequence and -noncoding RNA stabilization (Harrison & Shorter,
2017). On a broad level FUS mutations lead to deficits in RNA metabolism and dysregulation of
the mitochondrial manganese SOD gene (SOD2) transcription (Dhar et al., 2014). Despite some
overlaps between FUS and TDP-43, the majority of cases with FUS-immunoreactive
cytoplasmic inclusions are ubiquitin- and TDP-43-negative. A possible explanation for this
would be a shared FUS/TDP-43 pathway with FUS acting downstream of TDP-43 (Kabashi et
al., 2011; Renton et al., 2014). Nonetheless, the pathomechanisms of FUS have yet to be
thoroughly characterized.

UBQLN2 is an FTD/ALS-linked protein involved in the ubiquitin proteasome system (protein
degradation), and is also a constituent of TDP-43 inclusions. The presence of UBQLN2 in TDP43 aggregates occurs whether the disease manifests as sALS or fALS (Picher-Martel et al.,
2019). UBQLN2 and ubiquitin proteasome system dysfunction has been highly characterized in
the pathogenesis of ALS, with FTD concomitantly presenting in UBQLN2-ALS (Picher-Martel
et al., 2019; Renton et al., 2014). Specifically, UBQLN2 mutations result in dysregulated protein
degradation, which consequently, can cause aggregated proteins and neurodegeneration (Chen et
al., 2013). Moreover, UBQLN2 has been shown to directly interact with TDP-43. While the
significance of this is not clear, it is thought to enhance TDP-43 induced toxicity (Cassel &
Reitz, 2013; Picher-Martel et al., 2019).
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C9ORF72 is the most commonly mutated protein in fALS representing approximately 40% of
familial cases whereby a hexanucleotide repeat expansion mutation (HREM; GGGGCC) within
the gene produces degeneration (Gao et al., 2018; Heyburn & Moussa, 2017; Mathis et al.,
2019). An excess of 70+ HREMs is commonplace in mutated C9ORF72, whereas,
neurologically healthy subjects have ≤30 G4C2 HREMs (Gao et al., 2018; Heyburn & Moussa,
2017; Mathis et al., 2019). Notably, a C9ORF72 and TDP-43 link has been identified and
investigated, highlighting a correlation between HREM and perturbed trafficking,
mislocalization and accumulation of TDP-43 in the cerebellum of ALS patients (Heyburn &
Moussa, 2017).

The discovery of ubiquitinated TDP-43 (TARDBP) in both FTD and ALS provided the first
ground-breaking link between the two diseases (Gao et al., 2018; Renton et al., 2014). Mutated
TDP-43 represents approximately 4% of fALS cases and 2% of sALS cases, although TDP-43
proteinopathy is detected in 95-97% of ALS cases (Chen et al., 2013; Gao et al., 2018; Ling et
al., 2013; Renton et al., 2014). TDP-43 mutations are almost was located in the C-terminal
region (a prion-like low-complexity domain), and the location of these mutations has been
suggested to increase TDP-43 aggregation and self-assembly (Banks et al., 2008; Ling et al.,
2013; J. R. Mann et al., 2019). Given that TDP-43 is the primary focus of this investigation, the
following sections will discuss TDP-43 in greater detail.

1.8 TDP-43 Proteinopathy
TDP-43 is a 414 amino acid protein member of the heterogeneous ribonucleoprotein particle
family and is comprised of four functional domains. There is a nuclear localization sequence,
two RNA-recognition motifs and a prion-like low-complexity domain at the C-terminal, which is
rich in glycine (Banks et al., 2008; Boeynaems et al., 2018; Gasset-Rosa et al., 2019; Hansson et
al., 2019; J. R. Mann et al., 2019). Under normal physiological conditions TDP-43 is tightly
auto-regulated by controlling its own mRNA levels (via a negative feedback loop), and is a
predominantly nuclear protein (~70%), though it shuttles between the nucleus and cytoplasm
(Gao et al., 2018; Heyburn & Moussa, 2017; Hofmann et al., 2019; Sreedharan et al., 2008).
TDP-43 is involved in a multitude of functions such as transcription, translational regulation,
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RNA splicing, mRNA stability and RNA stress granule (SG) response (Gao et al., 2018;
Heyburn & Moussa, 2017; Hofmann et al., 2019). TDP-43 is capable of exerting its regulatory
effects via DNA/RNA binding, splicing and protein-protein interactions (Gao et al., 2018;
Heyburn & Moussa, 2017; Hofmann et al., 2019). The most frequent targets are RNA binding
sites, directing the regulation of mRNA splicing, translation, transportation and degradation (Gao
et al., 2018; Heyburn & Moussa, 2017; Sreedharan et al., 2008).

Under certain pathological conditions TDP-43 function can be disrupted leading it to become
neurotoxic. Furthermore, TDP-43 proteinopathy can manifest with or without the presence of
related genetic mutations. Several mechanisms have been proposed for these changes in TDP-43
activity. It remains unclear, however, what specific biological alteration(s) produce the ALS
pattern of neurodegeneration that causes TDP-43 dysregulation (Hofmann et al., 2019). An
aspect related to its dysregulation is the perturbation of TDP-43 trafficking between the nucleus
and cytoplasm, which is rooted in a number of effects related to its nuclear depletion and
accumulation in the cytoplasm (Gao et al., 2018). For example, loss of nuclear pore components
in natural aging can alter the distribution and concentration of TDP-43, inducing TDP-43
proteinopathy (D’Angelo et al., 2009; Gasset-Rosa et al., 2019). This might explain how TDP-43
proteinopathy can induce cognitive dysfunction and memory deficits in elderly individuals
lacking pathological diagnoses of FTD/ALS (Nag et al., 2017; Wilson et al., 2013). Of particular
importance, nuclear depletion of TDP-43 is not a requisite for the occurrence of neuronal toxicity
(Austin et al., 2014). However, the presence of mutant TDP-43 within the cytosol is sufficient to
produce neurodegeneration (Arnold et al., 2013a; Austin et al., 2014; Gao et al., 2018).

A critical component of ALS pathology is protein misfolding. Protein misfolding describes the
process of proteins transitioning from a normative conformation (normally folded), frequently
soluble confirmations, into altered or non-functional detergent-resistant confirmations
(misfolded; Gasset-Rosa et al., 2019; J. R. Mann et al., 2019). Notably, misfolded TDP-43 may
propagate in a prion-like fashion recruiting normally folded TDP43, increasing the propensity of
its normal counterpart to misfold and aggregate as well (Gao et al., 2018; Ling et al., 2013). In
the context of FTD/ALS, misfolded TDP-43 is critical for the generation of proteinaceous
inclusions comprised of full-length and or fragmented, misfolded and aggregated protein.
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However, protein misfolding and aggregation is also characteristic of other major
neurogenerative diseases such as AD, PD and Huntington’s disease (Gasset-Rosa et al., 2019; J.
R. Mann et al., 2019).

Characteristically, TDP-43 proteinopathy within an ALS-specific pattern of neurodegeneration
presents predominantly within the frontal and temporal lobes, orbitofrontal cortices, insular
cortex and spinal cord (Arai et al., 2006; Erkkinen et al., 2018; Heyburn & Moussa, 2017;
Hofmann et al., 2019). Neurodegeneration resulting from TDP-43 proteinopathy is observed in
95-97% of ALS cases, 50% of FTD cases and intriguingly over 50% of confirmed AD cases
(Gao et al., 2018; Ling et al., 2013). Moreover, TDP-43 proteinopathy is a documented
secondary pathological feature of other neurodegenerative diseases such as Huntington’s disease,
PD and AD (Banks et al., 2008; Gao et al., 2018; Heyburn & Moussa, 2017; Ling et al., 2013).
Nevertheless, a clear outline of the essential mechanism(s) underlying TDP-43 proteinopathy,
and the manner in which it contributes to neurotoxic and cognitive deficits, has not been
elucidated.

1.9 TDP-43 Propagation, Aggregation and Phase Transitions
The exact mechanisms that underlie TDP-43 proteinopathy and in what capacity it contributes to
neurotoxic functions has not been clearly defined. Specifically, it is unclear whether TDP-43
proteinopathy occurs due to a loss of function (via TDP-43 nuclear depletion), or a gain of
toxicity (via cytosolic misfolding and aggregation of TDP-43), which results in decreased cell
viability and neuronal loss. The prion-like low-complexity domain of TDP-43 has led to some
recent advancements in potentially establishing a more comprehensive understanding of the
pathomechanisms of TDP-43 proteinopathy. All identified TDP-43 mutations are situated in the
glycine-rich low-complexity domain , with the exception of a few discovered in RNArecognition motifs (Banks et al., 2008; Ling et al., 2013; J. R. Mann et al., 2019). Due to the
majority of mutations being located within low-complexity domains, and because lowcomplexity domains are common in RNA-binding proteins, they are quickly becoming a primary
focus of research into tauopathies and synucleinopathies (Boeynaems et al., 2018; Gasset-Rosa et
al., 2019; Ling et al., 2013; J. R. Mann et al., 2019). Low-complexity domains are also
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considered to be intrinsically disordered regions due to their composition consisting of only a
few amino acids that are repetitive in sequence (Boeynaems et al., 2018; Gasset-Rosa et al.,
2019; Ling et al., 2013). The composition of low-complexity domains makes them vulnerable to
rapid conformational alterations from their native state and self-assembly (Boeynaems et al.,
2018; Gasset-Rosa et al., 2019; J. R. Mann et al., 2019). The TDP-43 low-complexity domain is
also predominantly an intrinsically disordered region, which causes it to promote its own
aggregation (Gasset-Rosa et al., 2019; J. R. Mann et al., 2019).

Pathological TDP-43 which is mislocalized, misfolded and aggregated within cytoplasm can be
recruited or colocalized with SGs (Gao et al., 2018; Ling et al., 2013; Wolozin, 2019). SGs are
membraneless organelles, which under conditions of oxidative or cellular stress prevent nonessential protein translation by rapidly facilitating expression of protective proteins during a
stress response. SGs achieve this by sequestering, nucleating and compartmentalizing nonessential proteins and utilizing stalled mRNA pre-initiation complexes that have been stored
(Bozzo et al., 2017; Gao et al., 2018; Gomes & Shorter, 2019; J. R. Mann et al., 2019). ALS
disease pathology has been demonstrated to present with reduced nuclear import (stress;
compounded by reduced nuclear pore viability in natural aging), and mitochondrial dysfunction
which has been implicated in/with neuronal oxidative stress (Bozzo et al., 2017; D’Angelo et al.,
2009; Gao et al., 2019; Gasset-Rosa et al., 2019; Wang et al., 2017). Problematically, the
prolonged presence of these stress-inducing mechanisms may inadvertently cause SG seeding
behaviour and the enhancement of protein self-interactions. More specifically, SGs coalescing
with pathological TDP-43 and sequestering non-pathological correctly folded TDP-43 into
aggregates (Bozzo et al., 2017; Gao et al., 2019). Conformationally unaltered TDP-43
interactions with pathological TDP-43 may then induce the fibrilization of normally folded TDP43 via its intrinsically disordered prion-like low-complexity domains, likely leading to a loss of
function (Bozzo et al., 2017; J. R. Mann et al., 2019; Parker et al., 2012). Supporting this notion,
neurotoxic SG seeding behaviour has been ameliorated in a TDP-43 rodent model utilizing antisense oligonucleotide-mediated depletion of SG components providing evidence for potential SG
seeding behaviour in TDP-43 proteinopathy (J. R. Mann et al., 2019). Intriguingly, however,
immunohistochemistry and immunofluorescence reveals that neurotoxic SG formation and TDP-
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43 seeding behaviour is almost non-existent in tissue samples of ALS patients (Gasset-Rosa et
al., 2019).

Recently, it has been proposed that pathological TDP-43 granules are independent of SGs, with
SGs possibly serving as intermediaries for pathological TDP-43 to transition through (GassetRosa et al., 2019; J. R. Mann et al., 2019; Wolozin, 2019). The interactions between proteins and
RNA is mediated by low-complexity domains through a cellular mechanism known as liquidliquid phase separation (Boeynaems et al., 2018; Gasset-Rosa et al., 2019; Gomes & Shorter,
2019; J. R. Mann et al., 2019; Wolozin, 2019). Liquid-liquid phase separation is the process by
which molecules separate through condensation into liquid-like (not a liquid by classical
definition; associative polymers with physical crosslinks) compartments, producing distinct
coexisting dense and dilute phases (Boeynaems et al., 2018; Gasset-Rosa et al., 2019; J. R. Mann
et al., 2019). This process is promoted by weak and transient exchanges between low-complexity
domains and multivalent protein or nucleic acid interaction domains (Boeynaems et al., 2018;
Gasset-Rosa et al., 2019; J. R. Mann et al., 2019). This is contingent on specific types of the
cellular interactions (e.g, protein-protein, RNA-RNA, & protein-RNA), making intracellular
compartmentalization akin to that of membraneless organelles like SGs possible (Boeynaems et
al., 2018; Gasset-Rosa et al., 2019; J. R. Mann et al., 2019). The intrinsically disordered regions
determine the nature of phase transitions, including the density and organization of protein
modules contained in droplets through specific and non-specific protein and nucleic acid
interactions (Boeynaems et al., 2018; J. R. Mann et al., 2019). Critically, mutations residing in
the TDP-43 low-complexity domain modify liquid-liquid phase separation behaviour, increasing
the propensity for TDP-43 aggregation within droplets, and enhancing the rate of maturation and
fibrilization of originally reversible protein assemblies, resulting in droplet solidification
(Boeynaems et al., 2018). Indeed, this suggests that aberrant phase transitions may be implicated
in the formation of pathological TDP-43. This is supported by a recent optogenetic investigation
using a Cry2olig-TDP-43-mCherry expression construct (optoTDP43), which is able to trigger
light-induced TDP-43 proteinopathy and phase separation in cultured human (HEK293; ReNcell
VM) cells, and potentially seed endogenous TDP-43 aggregation (J. R. Mann et al., 2019). This
is also consistent with findings from a separate investigation of other RNA-binding proteins
(e.g., FUS), in which granule formation using arabidopsis cryptochrome-2 (Cry2) was optically
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induced (Shin et al., 2017). Additionally, support is provided by an in vivo optogenetic
investigation in zebrafish using light-stimulation of a mnr2b-hs BAC promoter driven Cry2oligtagged huTDP-43A315T expression construct (opTDP-43hA315T). Blue light stimulation of the
opTDP-43hA315T construct triggered pathological cytoplasmic aggregation of opTDP-43hA315T,
which induced seeding of non-optogenetic mnr2b-hs driven EGFP-tagged zebrafish TDP-43
(Asakawa et al., 2020).

The specific pathomechanism(s) causing aberrant phase transitions of TDP-43 have not been
delineated (Boeynaems et al., 2018; Gasset-Rosa et al., 2019; J. R. Mann et al., 2019). It has
been suggested, however, that this pathological process may be rooted in reduced nuclear import,
a component of natural aging, which may be exacerbated in ALS pathology (Boeynaems et al.,
2018; Gasset-Rosa et al., 2019). It is possible that reduced nuclear import then increases
cytosolic TDP-43 and dysregulates TDP-43 auto-regulation, increasing its synthesis and
accumulation. This cascade of events, including TDP-43 nuclear depletion, is likely sufficient to
induce cytoplasmic TDP-43 liquid-liquid phase separation causing cell death (Gao et al., 2018;
Gasset-Rosa et al., 2019; Heyburn & Moussa, 2017; Hofmann et al., 2019; J. R. Mann et al.,
2019; Wolozin, 2019)

1.10 Mutant TDP-43 Mouse Models
There is an urgent need for the development of new therapeutic strategies for patients afflicted
by FTD/ALS. Cognitive testing in mouse models of FTD/ALS can potentially expedite the
process of drug discovery by focusing on the cognitive aspects (executive dysfunction) primarily
affected in FTD/ALS (Kasper et al., 2015; Watermeyer et al., 2015). Given the predominant role
of TDP-43 in FTD/ALS pathology, in recent years many transgenic TDP-43 mouse models have
been developed to express human wild-type (WT) or FTD/ALS familial mutations of TDP-43.
These mutant mouse models are invaluable assets in the investigation of TDP-43 proteinopathy
given that they can recapitulate important features of both sALS and fALS pathology observed in
humans (Igaz et al., 2011; Swarup et al., 2011; Wegorzewska et al., 2009; Xu et al., 2011).
Furthermore, overexpression of wild-type and mutant forms of TDP-43 was shown to be
associated with protein aggregation and motor and cognitive deficits in TDP-43 mouse models
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(Arnold et al., 2013b; Swarup et al., 2011; Swarup & Julien, 2011). However, transgenic lines do
not perfectly recapitulate ALS pathology. Some mouse lines overexpressing mutant TDP-43
either display extremely aggressive disease progression reaching terminal end points too quickly
(4-8 weeks), lack ALS phenotypes and pathology, or are highly variable whereas others have
only mild phenotypes. Additionally, alternative TDP-43 transgenic mouse lines such as the TDP43flox/flox-VAChT-Cre knockout mice, although demonstrating ALS phenotypes, may not be as
representative of ALS disease pathology because of the knockout (Iguchi et al., 2013; Stallings et
al., 2010; Wils et al., 2010; Xu et al., 2010, 2011).

Accordingly, in the present work extra consideration was given to the appropriate selection of
mouse line(s) with phenotypes of low variability, reliable disease pathology and defined genetic
backgrounds. Furthermore, ensuring the diversification of mutations, promoters and levels of
expression of the selected mouse models may potentially facilitate a broader exploratory analysis
of FTD/ALS cognitive phenotypes, which might help delineate common cognitive phenotypes
despite different mutations. Based on available information and factors addressed above, we
opted to evaluate two unique transgenic mouse lines incorporating human FTD/ALS-linked
mutants of TDP-43 (TDP-43Q331Klow and TDP-43G348C). These models recapitulate some central
features characteristic to FTD/ALS pathology in humans, and are viable for 12-month long
investigations, allowing for studies of progressive changes in cognition. This is an encouraging
development, given that knowledge regarding the capacity of TDP-43 proteinopathy to elicit
cognitive alterations in mouse models is limited (although an intriguing ALS knock-in [KI]
mouse model became available, only after I started this work; White et al., 2018).

1.11 The TDP-43Q331Klow Mouse Model of FTD/ALS
The TDP-43Q331Klow transgenic mouse model was originally generated and characterized by Don
Cleveland’s group at the University of California (Arnold et al., 2013a). The mice were
generated to express the ALS-linked mutation huTDP-43*Q331K (lysine in position 331 instead
of glutamine) by injecting a vector containing N-terminal myc-tagged full length mutant TDP43Q331Klow driven by murine prion promoter. Generation of the mouse model was achieved
through random integration of complimentary DNA into the genome of a fertilized C57BL/6 X
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C3H hybrid. The TDP-43Q331Klow mouse model exhibits a very moderate 0.5-fold increase of
TDP-43 expression of normal endogenous mouse TDP-43 levels (this contrasts with a similar
model, TDP-43Q331K, which exhibits a 2.5-3-fold increase). Mutant TDP-43Q331Klow expression
driven by the prion promoter is predominantly expressed in the central nervous system,
specifically in brain and spinal cord neurons and astrocytes. Mutant TDP-43Q331Klow toxicity
induces the down-regulation of endogenous TDP-43 predominantly via TDP-43 auto-regulation.
(Arnold et al., 2013a; Jax Lab Prnp-TARDBP*Q331K, 2020).
The mutant TDP-43Q331Klow mouse line does not present with some pathological hallmarks of
TDP-43 proteinopathy such as TDP-43 nuclear depletion and mislocalization, cytoplasmic
inclusions, aggregation or truncated c-terminal fragments. However, the TDP-43Q331Klow mutant
mice still present with a progressive motor phenotype exhibiting minimal variation, where L5
ventral root motor axons and a neurons remain intact (Arnold et al., 2013a). At 3 months of age
there are identifiable differences in the development of tremors when comparing TDP-43Q331Klow
mutants to their non-transgenic (ntg) control and WT-huTDP-43 (overexpression without
mutation) counterparts. Due to the age-dependent nature of these deficits, motor function
progressively deteriorates. By 10 months of age there is a significant difference in the grip
strength of TDP-43Q331Klow mutants (Arnold et al., 2013a, 2013b). Evaluation of the TDP43Q331Klow mutants after 17 months of age revealed significantly stunted, if not stalled, motor
degeneration with minimal worsening post 10-months.
Postsynaptic neuromuscular junction quantification via gastrocnemius muscle α-bungarotoxin
staining revealed no reduction in neuromuscular junction endplates. Furthermore, morphological
evaluation of gastrocnemius muscle sections from 10-month-old TDP-43Q331Klow mutants
revealed no morphological abnormalities in the muscle fibres. Minor degeneration is present in
the spinal cord, specifically degeneration of descending corticospinal tracts of lateral and dorsal
columns. Generally, the TDP-43Q331Klow mutants exhibit functional deficits (decreased rotarod
performance) without significant alterations to the structural features of lower motor neuron
synapses, similar to ntg controls and WT-huTDP43. Cognitive alterations were not evaluated in
these mice (Arnold et al., 2013a).
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1.12 The G348C Mouse Model of FTD/ALS
The TDP-43G348C mutant mouse line was created by Jean-Pierre Julien’s group at Laval
University. The ALS-linked huTDP-43G348C mutation (cystine in position 348 instead of glycine)
was integrated into the mouse genome of a C57BL/6 X C3H fertilized hybrid using a bacterial
artificial chromosome clone and the endogenous promoter. The TDP-43G348C mutant mouse line
exhibits a 3-fold increase of TDP-43 expression compared with normal endogenous mouse TDP43 levels. In human ALS cases quantitative real-time analysis of spinal cord has shown a 2.5fold increase of TDP-43 mRNA, highlighting the similarity of the TDP-43G348C mutant mouse
model. The huTDP-43G348C transgene is also ubiquitously expressed in all tissues in which
normal endogenous mouse TDP-43 is expressed. Furthermore, endogenous murine TDP-43 is
down-regulated in the TDP-43G348C mutant mouse model (Swarup et al., 2011).
The TDP-43G348C mutant mouse line presents with nuclear depletion, mislocalization, and
cytosolic accumulation and aggregation of TDP-43, features closely recapitulating human TDP43 proteinopathy (Swarup et al., 2011). Critically, the TDP-43G348C mutant mouse model is
viable, whereas other overexpressing mutant TDP-43 lines have extremely rapid and aggressive
pathology rendering them unfit for investigations beyond a few weeks or months. Additionally,
the TDP-43G348C mutants present with age-dependent motor deficits, as indicated by accelerating
rotarod analysis. TDP-43G348C mutant mice exhibited significant differences in comparison to
ntg- and WT-huTDP-43 control mice as early as 8 months of age, with performance continuing
to deteriorate in an age-dependent manner. Furthermore, at 10-months-old L5 ventral root motor
axons of TDP-43G348C mutant mice remain intact (Swarup et al., 2011). Neuromuscular junctions
were also assessed in 10-months-old TDP-43G348C mutant mice with gastrocnemius muscle αbungarotoxin staining, revealing that up to 15% of neuromuscular junctions were denervated and
over 20% were partially denervated compared to ntg control mice (Swarup et al., 2011). At 3months-old the TDP-43G348C mutant mice revealed no morphological motor axon abnormalities.
However, 10-month-old TDP-43G348C mutant mice present with significant alterations to motor
axon morphology. Double immunofluorescence with NeuN and cleaved caspase-3 antibodies
indicated neuronal damage in the spinal cords of these mice (Swarup et al., 2011).
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Select cognitive aspects have been evaluated in the TDP-43G348C mutant mouse line, specifically,
spatial learning using the Barnes maze task and contextual fear responding/learning (Pavlovian
fear conditioning) with a step-through passive avoidance light-dark box. These tasks revealed
TDP-43G348C mutant mice demonstrate age dependent contextual and spatial memory deficits
between 7-10 months. Nonetheless, executive dysfunction has not yet been evaluated in the
TDP-43G348C mutant mouse line (Swarup et al., 2011).

1.13 Automated Touchscreens and Translation
Neurological diseases are extremely complex and the initial changes are often subtle and difficult
to consistently and accurately assess; thus the use of sensitive/selective tests is particularly
important in this area (Gaskin et al., 2017; Van den Broeck et al., 2020). Conventional cognitive
testing methodologies often have large variations across laboratories, and despite efforts to
control for such variances in conventional testing, different experiments may still produce
differing results. Generally, the evidence suggests a propensity for non-automated and nonstandardized conventional cognitive testing methodologies to be unintentionally variable (e.g.,
animal handling variances, effect of experimenter sex and smell & testing methodology variance;
Beraldo et al., 2019; Crabbe et al., 1999). For this reason, the automated touchscreen system
developed by Tim Bussey and Lisa Saksida (principal investigators of our lab) and their
collaborators has been adopted for use in this investigation. Globally there are about 300
laboratories, about 25% percent of them represented by pharmaceutical companies, using
touchscreen technology for cognitive testing in rodents (Beraldo et al., 2019; Dumont et al.,
2020). Automated touchscreens have been adopted largely due to their utility and consistency
across laboratories in detecting cognitive alterations and differences in common mouse lines and
neurodegenerative diseases (Beraldo et al., 2019; Bussey et al., 2008; Dumont et al., 2020;
Horner et al., 2013). These touchscreen systems are consistent across laboratories in terms of
tests, protocols, and parameters, and are identical to human cognitive evaluations in certain
situations, facilitating translation (Bussey et al., 2008; Graybeal et al., 2014; Heath et al., 2019;
Horner et al., 2013; Nithianantharajah et al., 2015; Romberg et al., 2013). Automated
touchscreens provide a multitude of benefits including, but not limited to, computer controlled
standardized protocols (inter-trial interval, delay periods, stimulus presentations, etc.),
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heightened cognitive impairment sensitivity, high throughput capability, inter-laboratory
replicability and critically, significantly diminished experimenter and environmental influence
(Beraldo et al., 2019; Dumont et al., 2020). Furthermore, automated touchscreen tasks/protocols
are not reliant on intact motor abilities, allowing mice with motor dysfunction to be evaluated
without major impacts on the results (Morton et al., 2006).

1.14 Touchscreen Evaluation of Cognition in Mice
A steadily growing selection of touchscreen tasks for evaluating different aspects of cognition in
rodents is now available. Here, we looked to evaluate distinct mouse models of TDP-43
proteinopathy (TDP-43Q331Klow & TDP-43G348C) to test for robust cognitive phenotypes across
these mouse models, which could then be used in the identification of therapeutic targets and
drug development. For this purpose, features of executive function dysregulated in FTD/ALS
were assessed in these mice with specific tasks: attention (5-choice serial reaction time task [5CSRTT]), cognitive flexibility (pairwise visual discrimination [PVD] and reversal), long-term
learning and memory (paired associates learning [PAL]), and motivation/apathy (progressive and
fixed ratio [PRFR]). As discussed previously, these features of executive function are reported to
be dysregulated prior to the onset of classical motor symptoms in human ALS (Lomen-Hoerth et
al., 2003; Strong et al., 2003). The sensitivity to impairments afforded by automated
touchscreens may enable detection of similar cognitive impairments in TDP-43 mutant mouse
models prior to motor dysfunction. This manner of testing aligns with similar computerized tasks
used to investigate the same features of executive function in other human neurodegenerative
diseases, including ALS (Barson et al., 2000; Heath et al., 2019; Stojkovic et al., 2016). All tasks
used herein have already been established and validated by our lab, former lab members and
collaborators.

1.15.1 Pairwise Visual Discrimination (PVD) Task and Reversal
The PVD and reversal task evaluates learning ability and cognitive flexibility, which is the
ability to alter behaviour, based on a shift in rules, patterns or contingencies. Cognitive flexibility
is assessed through the presentation of two visual stimuli simultaneously, which are initially
preferred equally by the rodent. The rodent is required to learn that a response (nose-poke) to
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only one of these visual stimuli is rewarded (S+), whereas the other visual stimulus (S-) is not
rewarded. Once the animal has acquired the task, the reward which was contingent on selection
of the S+ is reversed. Following this reversal, the previous S+ is unrewarded (new S-) and the
previous S- is rewarded (new S+). During acquisition, the animal must visually discriminate
between equally preferred stimuli and acquire the stimulus-reward relationship. Subsequent to
the reversal of this relationship, the animal must be able to inhibit its prepotent responses to the
previously rewarded stimulus and simultaneously acquire the new stimulus-reward relationship.
The ability to be cognitively flexible is disrupted in FTD/ALS patients (Gao et al., 2018; Machts
et al., 2014; Zakzanis, 1998). Furthermore, the reversal component of the PVD task is dependent
on the orbitofrontal cortex and striatum, areas known to degenerate in FTD/ALS pathology
(Erkkinen et al., 2018).
1.15.2 Different Paired Associates Learning Task (dPAL)
The dPAL task evaluates visuospatial memory and adopts the important components of the
Cambridge Neuropsychological Test Automated Battery PAL, a highly sensitive task which is
used to discriminate between sufferers of early-stage AD and individuals afflicted by cognitive
impairment stemming from different neurological conditions such as FTD/ALS (Lee et al.,
2020). Visuospatial memory performance is evaluated by presenting rodents with unique visual
stimuli in two of three possible spatial locations, which they are required to nose-poke. A single
compound (shape-location) stimulus is always positively associated with reward (S+), and one is
always associated with a punishment (S-) in the form of a tone and time-out delay. Although
visuospatial performance has been reported to be relatively spared in FTD/ALS pathology,
because of the success of PAL in mouse and human studies of neurodegenerative disease, TDP43Q331Klow & TDP-43G348C were evaluated with this task (Erkkinen et al., 2018).

1.15.3 5 Choice Serial Reaction Time Task (5-CSRTT)
The 5-CSRTT evaluates sustained attention, one of the principle cognitive abilities affected by
FTD/ALS, even early in disease progression (Igaz et al., 2011; Mantovan et al., 2003; Zakzanis,
1998). The 5-CSRTT requires the animal to respond to a momentary and spatially randomized
light stimulus in one of five possible locations arranged in a horizontal line. Responses are
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recorded by nose-pokes to the light stimulus. There is a substantial number of metrics evaluated
in this task, the primary ones being accuracy (response to correct location), premature responses
(response before stimulus presentation), omissions (failure to respond), perseverative responses
(continued responding following previously correct stimulus response), as well a number of
latency metrics (correct response latency, incorrect response latency & reward collection
latency). Initial training conditions for the 5-CSRTT are relatively lenient, using 4 second and 2
second stimulus illumination durations. Once an animal has reached criterion (80% accuracy,
fewer than 20% omissions) probe trials can be initiated. The animals are then evaluated with four
novel stimulus illuminations duration for two consecutive days each (1.5s, 1.0s, 0.8s, and 0.6s).
The shorter the stimulus illumination duration, the greater the demand on attention to
successfully perform the task.

1.15.4 Progressive Ratio Fixed Ratio Task (PRFR)
The PRFR task evaluates motivation and apathy in rodents. Apathy is also a condition observed
in human FTD/ALS (Radakovic et al., 2016; Zamboni et al., 2008), and a variant of this task is a
part of the EMOTICOM battery used previously by our lab (Heath et al., 2019). The PRFR task
has been previously described by our lab (Heath et al., 2016). Motivation/apathy is evaluated by
requiring the subject to respond (via nose-poke) to a visual light stimulus (illuminated white
square; which always appears in the same location), which appears centrally on a screen to
receive a reward. The animal is required to elicit a predetermined number of responses, based on
the ratio selected, to obtain reward. There is a substantial number of metrics evaluated in this
task, the primary ones being target touches (correct response), breakpoint (highest number of
responses within last trial), blank touches (response to non-illuminated window) and trials
completed.

1.15 Investigation Objective
There is substantial heterogeneity in the clinical presentation, disease progression and disease
outcomes of FTD/ALS (Banks et al., 2008; Chen et al., 2013; Chiò et al., 2018; Hardiman,
2010). Furthermore, the heterogenous nature of FTD/ALS creates significant difficulty in the
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identification of a key common neuropathological mechanism inherent to all FTD/ALS patients,
and in fact such a mechanism may not exist. However, FTD/ALS share overlapping clinical and
genetic features, and TDP-43 proteinopathy is present in 95-97% of all ALS cases, and 45-50%
of all FTD cases (Gao et al., 2018; Ling et al., 2013; I. R. Mackenzie & Neumann, 2017). Thus,
TDP-43 proteinopathy cuts across the FTD and ALS continuum. In light of the importance of
TDP-43, and combined with the importance of (premorbid) cognitive deficits in both FTD and
ALS discussed above, in the present study we focused on the question of how TDP-43 mutations
in TDP-43Q331Klow and TDP-43G348C mice affect cognition. While TDP-43Q331Klow and TDP43G348C mice have not been comprehensively evaluated for their cognitive abilities. I
hypothesized that TDP-43 mutations impair cognition in mouse models of FTD/ALS, appearing
earlier than motor dysfunction using automated touchscreen technology and validated tasks. If
the automated touchscreens can reveal an early cognitive phenotype across the two FTD/ALS
mutant mouse models (TDP-43Q331Klow and TDP-43G348C), there might be potential to accelerate
the identification of therapeutic targets and the development of treatment options capable of
acting on the neuropathological mechanism(s) afflicting 95% of ALS and nearly 50% of FTD
patients.

2. Materials and Methods
2.1 Q331KLow Mice
The TDP-43Q331Klow mice [Tg(Prnp-TARDBP*Q331K)109Dwc/line 109/ Stock number 017930]
and littermate control mice (C57BL/6NJ; Stock number 005304) used in this study were
generated at Western University and bred from commercially available mouse lines obtained
from Jackson Laboratories (Bar Harbor, Maine). The TDP-43Q331Klow mice were heterozygous
for the ALS-linked Q331K mutation (huTDP-43*Q331K) and driven by the murine prion
promoter.
The mice utilized in this study, twenty-seven TDP-43Q331Klow males and eighteen C57BL/6NJ
wild-type littermate controls were between three and four months of age during the start of
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behavioural testing. At this age TDP-43Q331Klow mice present no deficits in motor performance
(Arnold et al., 2013a).

2.2 G348C Mice
The TDP-43G348C mice used in the study were graciously provided by Dr. Jean-Pierre Julien
(Centre de Recherche du Centre Hospitalier Universitaire de Québec; Laval University) and
subsequently bred at the University of Western. Cohorts of littermate control mice generated at
Western University were bred from a commercially available control line (C57BL/6J; Stock
number 000664) obtained from Jackson Laboratories (Bar Harbor, Maine). The TDP-43G348C
mice were heterozygous for the ALS-linked G348C mutation (huTDP-43*G348C) and were
generated through amplification of TARDBP (NM_007375) by polymerase chain reaction from
a human bacterial artificial chromosome clone (clone ROCI-11, number 829B14) and the
endogenous promoter (Swarup et al., 2011). The TDP-43G348C model expresses a 3-fold
increase in TDP-43 compared with normal endogenous mouse TDP-43 levels (Swarup et al.,
2011).
The twenty-two TDP-43G348C male mice and fifteen C57BL/6J wild-type littermate controls
ranged between three and four months at the commencement of behavioural testing. The TDP43G348C present no deficits in motor performance at this age (Swarup et al., 2011).

2.3 Ethics
Animals used throughout this study were all monitored, handled and maintained by myself, or
otherwise University of Western Animal Care and Veterinarian Services. Animal use protocols
(2016-103; 2016-104) and procedures were in compliance with approved animal use protocols at
the University of Western, and in line with the Canadian Council of Animal Care stipulations.

2.4 Housing, Food Restriction
Animals were housed in an enclosed colony room specifically designed for the maintenance of
mice. The housing room is regulated by a standard automated 12-hour light/dark cycle (lights on
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at 7:00 A.M.). Colony room air humidity and temperature was also regulated by an automated
system and was held between 40%-60% and 22-25oC respectively. All mice were housed
individually in clear polyethylene containers (19.56cm x 30.91cm x 13.34cm). The containers
were shelved using Maxi-Miser positive individually ventilated systems, commercially available
at Thoren Caging Systems Inc (Hazelton, Pennsylvania). Animal enrichment was not provided.

All animals underwent food restriction one week prior to behavioural testing and were
maintained at 85% of their free feeding weight until sacrificed. Food provided to animals ranged
between 1-3 grams (3.35kcal/gram) of precut pellets with a macronutrient breakdown of 21.3%
protein, 3.8% fat, 54% carbohydrates, and 20.9% micronutrients/other. Precut dustless food
pellets are commercially available at Bio-Serv (Flemington, New Jersey). Water was available
ad libitum unless specifically noted otherwise. Food treats were not provided.

2.5 Locomotion Apparatus
Animal locomotor behaviour was assed using open field locomotor activity boxes produced by
Omnitech Electronics (Columbus, Ohio). The locomotion boxes were paired with Fusion
software allowing 32 animals to be assessed simultaneously and the complete experimental data
of each animal to be individually recorded. The locomotor boxes used for behavioural testing
were specifically designed for mice. The locomotor boxes were constructed of clear polyethylene
with ventilation holes integrated into the lid. A set of 16 infrared beam arrays are also integrated
into the locomotor boxes along the horizontal X and Y axes. The hardware uses these beams for
the detection of the animal within space and its behavioural orientation. The software can
produce a number of analyses from detected rodent behaviours.

2.6 Grip Force Apparatus
Animal neuromuscular function performance was evaluated using a grip force apparatus
obtained through Columbus Instruments (Columbus, Ohio). The grip force apparatus specifically
evaluates peak force exerted by the animal when grasping the pull bar assembly. The pull bar
assembly used for neuromuscular function performance was specifically designed for mice.
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Motor performance readouts were displayed on the digital screen built into the apparatus and
manually recorded.

2.7 Wire Hang Apparatus
The sustained neuromuscular function performance of animals was also assessed using a wire
hang apparatus. The animals were suspended upside down from a metal grate elevated 60 cm
from its base. The amount of time that elapsed between the animal being mounted and
dismounting into a soft bedding-filled pit was then manually scored and recorded.

2.8 Touchscreen Apparatus
Behavioural investigations were conducted using the automated Bussey-Saksida touchscreen
testing system (model 80614; Lafayette Instruments, Lafayette, Indiana) designed for mice. The
touchscreen apparatus is constructed in a trapezoidal shape and is situated within a chamber that
blocks external light and attenuates sound. Heat from the touchscreens is managed by fans built
into each chamber keeping the temperature between 22-24oC. These fans also diminish any
potential noise pollution from neighbouring chambers. The space accessible to the animal, and
where behavioural testing occurs is 46mm wide at the reward magazine tray, 238mm wide at
touchscreen and 170mm Deep (241.4 Sq. cm). The floor of the touchscreen apparatus is a
perforated grate floor with circular cut-outs. The touchscreen chambers all feature built in
speakers, and a light built into the top of the enclosing chamber where cameras are also mounted.
The reward magazine tray is built into the narrow end of the apparatus opposite of the
touchscreen and administers liquid reward. The liquid reward is pumped through replaceable
tubing into a metal opening within the reward magazine tray. Infrared beams are also integrated
into the reward magazine tray to detect animal entry and exit of the reward magazine tray.
Additionally, responses to the touchscreens (12.1 in.; resolution 800 x 600) are detected with
infrared beams to enhance the accuracy of animal touch response detection. Unintentional
responses by animals (e.g., responses elicited by tails) is prevented through the use of black
perspex masks that have task-specific cut-outs. The touchscreen testing system is mated to
ABET II software (Lafayette Instruments) produced by Lafayette Instruments which controls the
touchscreens in each individual chamber and records behavioural responses.

28

2.9 Rodent Shaping
The touchscreen testing system necessitates instrumental responses, and animal shaping
procedures utilize appetitive conditioning to promote such behaviours through training. Mice are
trained through a series of phases that progressively shapes appropriate touchscreen responding.
Food restriction is also implemented to enhance the effectiveness of food reward as an appetitive
motivator. Although a sizable variety of tasks exist for touchscreen testing, largely the training
consists of a few stages which are highly similar, followed by task-specific training. The shaping
procedure is a 7-step process for the tasks used herein (5-CSRTT, PRFR, PVD & PAL), and are
nearly identical throughout with slight variations to omissions, correction trials and inter-trial
intervals (ITI; 5 – 20s). To provide further clarification, the animals which complete the initial
shaping procedures and subsequent task-specific training do not undergo shaping again (except
where necessary) if they are immediately transitioned to another touchscreen task (e.g., 5CSRTT progressing to PRFR task). Additionally, mice were permitted only one session
(training/probe trial) per day.

Neilson brand strawberry milkshake was utilized as liquid food reinforcer (task-dependent
volumes; 7μl, 21μl & 150μl) to maintain animal motivation during the course of touchscreen
testing. Neilson branded milkshake is commercially available through Saputo (Montreal,
Quebec).

2.10 5-CSRTT Shaping
2.10.1 Stage 1: The first phase (Habituation-1), allowed the animal to briefly acclimate
themselves with the testing chamber environment for a period of 10 minutes. All features of the
touchscreen system and chamber were switched off during this time (no stimuli or reward) with
the exception of the camera (house light off) and ventilation fan.

2.10.2 Stage 2: Across the following two days the mice underwent Habitituation-2a. During
habituation-2a the mice were allotted 20-minutes of exposure to the testing chamber environment
with all features of the touchscreen testing system enabled, including liquid strawberry
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milkshake reward. Habituation-2a allowed for unlimited trials during the 20-minute period. The
first trial was initiated with the reward magazine tray light turned on; a tone (3Khz; 1000ms) was
subsequently played, while strawberry milkshake was simultaneous dispensed (150μl) into the
reward magazine tray. The ABET II program then waited for the mouse to enter the magazine
tray (detected by IR beams); once the mouse withdrew from the magazine tray the light turned
off. After 10 seconds elapsed the magazine tray light turned back on. However, during this trial,
and all trials that followed the milkshake reward was reduced to 7μl with the tone duration
unchanged. If the mouse had pre-emptively entered the magazine tray an extra second would be
added to the delay period. This process was repeated until the 20-minutes expired, at which point
the animal was immediately removed from the testing chamber.

2.10.3 Stage 3: The final habituation phase was Habituation-2b. Here the animals remained in
the testing chambers for 40-minutes. The animals also underwent the same reward administration
protocol as described in stage 2.

2.10.4 Stage 4: This is the first phase which encouraged the mouse to interact with the
touchscreen and is referred to as initial touch. The mouse was placed into the testing chamber
with the house lights off. A maximum of 30 trials were permitted and time was capped to 60
minutes. A stimulus was also presented in this phase; an illuminated white square (4 x 4cm)
appearing in 1 of 5 possible locations within the 5-CSRTT specific perspex mask cut-out. The
stimulus was only presented in one location at a time; all other windows locations were blank.
The stimulus was also presented in a pseudo-random fashion, preventing a position from being
repeated in succession more than 3 times. The stimulus presentation lasted 30 seconds, following
this the image was automatically removed and milkshake was administered into an illuminated
reward magazine tray (7μl) paired with a tone (3Khz; 1000ms). IR beam detection of the mouse
entering the reward magazine tray turned of the light and initiated an ITI (5 seconds). Once the
ITI ended another stimulus was presented. A response to the screen in the location in which the
stimulus was presented removed the stimulus presentation and immediately administered 3 times
the milkshake reward (21μl). Following reward collection by the mouse, the ITI was reinitiated,
and the next stimulus was then presented.
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2.10.5 Stage 5: The next phase of the shaping procedure is called must touch. The mice were
given a maximum of 30 trials to be completed within a 60-minute period. Tone and ITI
parameters were identical to stage 4. Must touch required the mouse to respond to the stimulus
presented in 1 of 5 possible locations. However, the mouse was required to touch the stimulus to
trigger the tone and milkshake reward administration. Blank window touches and elapsed time
produced no response from the testing system; the mouse was required to touch the correct
stimulus. Successful responses, reward collection and withdrawal from the reward magazine tray
started the ITI, followed by another stimulus presentation. 30 trials completed within 60-minutes
was required for progression to stage 6.

2.10.6 Stage 6: This phase is referred to as must initiate. The trial, time, tone and ITI parameters
for must initiate were identical to stages 4 and 5. Once the must initiate schedule began the
reward magazine tray was illuminated and a free 7μl of milkshake was dispensed. The mouse
was required to enter and withdraw from the reward magazine tray before the first trial could
commence. Every subsequent trial was required to be initiated in the same manner. The reward
magazine tray was illuminated (no free reward), and the mouse was required to nose poke into
the reward magazine tray and then withdraw. The stimulus was then presented in 1 of 5 possible
locations. A successful response, reward collection and withdrawal from the reward magazine
tray initiated the ITI, followed by the reward magazine tray being illuminated again. 30 trials
completed within 60-minutes was required for progression to stage 7.
2.10.7 Stage 7: This phase continues “must initiate” training and following an ITI, added in the
requirement for mice to abstain from touching incorrect locations. This phase is referred to as
punish incorrect and as in stages 4 – 6 the trial, time, tone and ITI parameters were identical.
Punish incorrect mimicked stage 6 with a key alteration: incorrect responses to a non-illuminated
window (e.g., not the stimulus) resulted in a timeout with a bright house light being turned on for
5 seconds and no reward provided. Once the 5 seconds had elapsed the ITI (5 seconds) began
and the mouse was required to complete a correction trial (stimulus location from previous trial
repeated). Correction trials were repeated until the mouse correctly responded subsequently
eliciting administration of the tone and reward.
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Figure 1. Flow chart of general shaping schedule prior to task specific training.
2.11 5-CSRTT Training
2.11.1 Stage 8: 5-CSRTT training to baseline-4s stimulus was the first training phase. The 5CSRTT training was used to establish a baseline in performance. The parameters for max
schedule time, tone, ITI, reward volume and incorrect response ITI were unchanged from stages
4 – 7. The maximum number of trials during training was constant at 50. The training session
commenced with the reward magazine tray being illuminated and primed with 7μl of free
milkshake reward. Withdrawal from the reward magazine tray initiated the first trial with a 5
second delay interval. Following the delay, the stimulus was presented in 1 of 5 possible
locations pseudo-randomly. Stimulus responses were required to be initiated within a set
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timeframe. A mouse could respond to the stimulus (white square) during the 4 second
illumination period in the location it was presented. If the mouse failed to respond, there was a
limited hold period lasting 5 seconds. During this window of time, a response at the location in
which the stimulus was presented was considered to be correct, and subsequently triggered the
reward magazine tray to illuminate and dispense milkshake reward (7μl) paired with a tone
(3Khz; 1000ms). Withdrawal from the reward magazine tray then initiated the ITI, after which
the reward magazine tray was re-illuminated allowing the mouse to progress to the next trial by
entering and withdrawing from the reward magazine tray. Incorrect responses, premature
responses (response during 5s delay), and omissions (failure to respond within limited hold
period) resulted in a 5 second timeout paired with the house light turned on. Once the timeout
had expired the house light turned off and the ITI-incorrect began, lasting 5 seconds. The 4
second stimulus training was continued until the mice were able to reach criterion (≥80%
accuracy [total correct trials / total number of trials with response] & ≤20% omissions [total
trials missed / total trials presented]) for three consecutive days.

2.11.2 Stage 9: 5-CSRTT training to baseline-2s stimulus was the second training phase. Within
this stage the stimulus duration was reduced from 4 seconds to 2 seconds, all other training
conditions and parameters were identical to stage 8, including criterion thresholds. Where
necessary, animals that met criterion before their counterparts were placed on maintenance and
repeated stage 9 once per week.

2.12 5-CSRTT Probe Trials
Following completion of stage 9 the mice were evaluated with four novel stimulus durations
(1.5s, 1.0s, 0.8s, & 0.6s). By reducing the duration of stimulus presentations, the demand on
attention is increased making the task more challenging. Each stimulus duration was completed
for two consecutive days followed by two consecutive days of a baseline 2 second stimulus
duration before transitioning to the next probe. Performance was evaluated using the criterion
outlined in stages 8 and 9, however, there was no requirement to meet the criterion thresholds to
progress through probe trials.
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2.13 Investigation Time Points
The mice were evaluated longitudinally as they aged with the first probe trials being completed
while the mice were 4 – 5 months old. The mice were then placed on a maintenance schedule
with a 2 second stimulus duration until they reach the desired age. Maintenance was performed
once per week on the same day (e.g., Friday), also ensuring to keep the time of testing consistent.
This process was necessary to ensure the animals would not require retraining. The second time
point was completed when the mice were 8 – 9 months old.

2.14 PRFR Shaping
Shaping for the PRFR task was completed prior to 5-CSRTT Training. Refer to rodent shaping
and 5-CSRTT training (sections 2.11 & 2.12 respectively).

2.15 PRFR Training
2.15.1 Stage 9a: This stage was comprised of a variety of fixed ratio (FR) training schedules
starting with FR1. The FR1 schedule required the mice to complete 30 trials within 60-minutes.
Within a trial a single operant response elicited a single food reinforcer. Each trial presented the
stimulus indefinitely within the central window (5-SCRTT Perspex mask; section 2.11, stage 4).
The stimulus was removed once the mouse had successfully responded. For this single correct
response, a tone was played (3Khz; 1000ms) and strawberry milkshake reward (7μl) was
delivered simultaneously into the illuminated reward magazine tray. Following withdrawal, the
magazine tray light turned off and an ITI (4.5s) began before the next stimulus presentation.
Once the mice reached criterion (30 trials within 60-minutes; single session) they immediately
progressed to FR2.

2.15.2 Stage 9b: The FR2 schedule was identical to that of the FR1 schedule with the exception
of two key alterations. Here, the reinforcer requirement was increased to two operant responses
for administration of a single food reinforcer. Additionally, continual responding to the stimulus
was promoted by its brief removal (500ms), following a successful response indicated by a
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single rapid audible chirp (3Khz; 10ms). Once the mice reached criterion (30 trials within 60minutes; single session) they immediately progressed to FR3.

2.15.3 Stage 9c: The FR3 schedule was identical to that of FR2, with exception of three operant
responses being required for administration a single milkshake reinforcement. Once criterion was
met (30 trials within 60-minutes; single session) the mice immediately progressed to FR5.

2.15.4 Stage 9d: The FR5 schedule was identical to that of FR2/3, with exception of five operant
responses being necessary for delivery of a single milkshake reinforcement. Once criterion was
met (30 trials within 60-minutes; two consecutive sessions) the mice immediately progressed to
PR testing.

2.15.5 Stage 10: This stage was comprised of a variety of PR testing schedules. PR4 was the first
of these schedules requiring mice to complete as many trials as possible within a 60-minute
session. All PR schedules started in the same manner, requiring a single operant response to
obtain a single food reinforcer (7μl) from the illuminated reward magazine tray, which coincided
with a tone (3Khz; 1000ms). Following reward collection and withdrawal from the reward
magazine tray, an ITI (4.5s) was initiated before the next stimulus presentation. All subsequent
trials increased on a linear ramp (e.g., PR4 ramp; 1, 5, 9, 13…responses per trial) where repeated
touches were promoted by a brief removal of the stimulus (500ms), following a successful
response signaled by a single rapid audible chirp (3Khz; 10ms). Sessions could be completed by
reaching the maximum time limit, or terminated if no response to the screen, or reward magazine
tray entry was detected within a 5-minute period. This process was repeated three times
consecutively.

2.15.6 Stage 11: Following PR4 the mice were returned to FR5 for two days (section 2.16, stage
9d) to mitigate potential performance deterioration due to repeated subjection to the PR schedule.

2.15.7 Stage 12: Following stage 11 the testing from stage 10 was repeated for another three
consecutive days (section 2.16, stage 10).
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2.15.8 Stage 13: During this stage the mice went through a three-day high-demand PR block,
with the linear ramp being increased each day starting with PR4 (n +4), then PR8 (n +8) and
concluded with PR12 (n +12). The testing protocol is as described in stage 10 (section 2.16),
however each schedule was completed only once.

2.15.9 Stage 14: Following the high-demand PR block the mice were returned to FR5 two days
(section 2.16, stage 9d) to prevent any potential performance deterioration due to repeated
exposure to the PR schedule.

2.15.10 Stage 15: Here, the mice went through a final high-demand PR block as described
previously (section 2.16, stage 13) before testing was completed.

2.16 PVD Shaping
As stated previously, the training schedule is largely unchanged across tasks. However, the PVD
task does have some slight modifications noted where applicable.

2.16.1 Stage 1: Habituation 1; refer to 5-CSRTT training (section 2.11).

2.16.2 Stage 2: Habituation 2a; refer to 5-CSRTT training (section 2.11).

2.16.3 Stage 3: Habituation 2b; refer to 5-CSRTT training (section 2.11).

2.16.4 Stage 4: Initial Touch; refer to 5-CSRTT training (section 2.11).
Modifications: ITI 20s; Selected shape stimulus (1 of 40 chosen randomly) not designated for
testing (acquisition/reversal) presented in 1 of 2 possible window locations (location without
stimulus is blank) within the PVD specific perspex mask cut-out.

2.16.5 Stage 5: Must Touch; refer to 5-CSRTT training (section 2.11).
Modifications: Refer to stage 4.
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2.16.6 Stage 6: Must Initiate; refer to 5-CSRTT training (section 2.11).
Modifications: Refer to stage 4.

2.16.7 Stage 7: Punish Incorrect; refer to 5-CSRTT training (section 2.11).
Modifications: No correction trials, no omissions (stimulus duration infinite); Refer to stage 4.

2.17 PVD Training
Stage 8: This is an acquisition phase, where the mouse was required to utilize the visual features
of two different stimuli presented simultaneously to learn a stimulus-reward relationship. During
the PVD acquisition phase the maximum number of trials was capped at 30 and the schedule
timer was limited to 60 minutes. Additionally, timeouts paired to the house light were set to 5
seconds, ITI was 20 seconds, tone was 3Khz lasting 1000ms and paired with the milkshake
reward (7μl). To initiate the session, 7μl of free milkshake reward was primed in the reward
magazine tray, once the mouse withdrew the first trial began (detected by IR beams). A
simultaneous presentation of S+ and S- stimuli in the two widows then followed. The stimuli
were presented pseudo-randomly, such that image location repetitions did not exceed three
consecutive left or right presentations. Correct responses to the S+ then simultaneously elicited a
tone and reward administration into the illuminated reward magazine tray. Withdrawal from the
reward magazine tray triggered the ITI. Once the ITI had ended, the reward magazine tray
illuminated and the mouse was required to enter and withdraw to initiate the next trial. Incorrect
responses (touching the S-) resulted in a 5 second timeout paired with the house light turning on.
Once the timeout had expired the house light turned off and the ITI-incorrect began, lasting 20
seconds. Following the ITI the reward magazine tray was illuminated and the mouse was
required to enter and withdraw to complete a correction trial. Correction trials presented the S+
and S- from the previous trial in their prior spatial locations. This was repeated for each
subsequent trial until the mouse correctly responded to the S+. Correction trial responses did not
contribute toward completion criterion for the session. Once the mice have reached criterion
(24/30 correct for two consecutive days) they were transitioned to the next stage.
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2.17.1 Stage 9: Immediately following stage 8 the performance of the mice was baselined for
two consecutive days. The protocol was identical to stage 8, however, there was no correct
response threshold requirement to progress to the next stage.

2.17.2 Stage 10: This stage is referred to as reversal. All conditions, penalties and parameters
were identical to that of stages 8 and 9, with one exception. The stimulus-milkshake reward
pairing was reversed. Here, the previous S+ is unrewarded (new S-) and the previous S- is
rewarded (new S+). Correction trial results did not contribute toward completion criterion for the
session.

2.18 dPAL Shaping
Shaping for mice being investigated with the dPAL task was completed prior to PVD Training.
Refer to rodent shaping and PVD training (sections 2.11 & 2.18 respectively).

2.19 dPAL Training
2.19.1 Stage 8: This is an acquisition phase, where the mouse was required to utilize the
combined visual and spatial features of two distinct stimuli presented simultaneously to acquire
correct image and location pairings. The dPAL task utilized a triple window perspex mask
layout. During dPAL acquisition the maximum number of trials was 36, with the schedule timer
terminating sessions after 60-minutes. Additionally, the ITI was locked to 20 seconds, tone was
3Khz lasting 1000ms and paired to the milkshake reward, which had its distribution volume set
to 7μl. To start the session 7μl of free milkshake was primed in the reward magazine tray, once
the mouse withdrew from the reward magazine tray the first trial began (detected by IR beams).
A simultaneous presentation of a S+ image/location coupling and a S- image/location coupling
was then presented in 2 of 3 windows, the third window was blank. Correctly responding to the
S+ image/location elicited a tone concomitant with the administration of milkshake
reinforcement into the illuminated reward magazine tray. Once the mouse withdrew from the
reward magazine tray the ITI started. Following the ITI the mouse was then required to enter and
withdraw from the reward magazine to progress to the next trial. Importantly, incorrect responses
did not elicit a delay time out period, further an omission feature was not present. Mice could not
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progress to subsequent trials without a correct response being made. Progression criterion was
set to 36 trials completed within a single 60-minute session.

2.19.2 Stage 9: The dPAL evaluation stage immediately followed stage 8, and consisted of 45
sessions (5 sessions [1 bin] per week) . Parameters for number of trials, schedule timer, ITI, tone,
and milkshake reinforcer administration were all identical to stage 8. The demands of the task
during the dPAL evaluation phase differed only with the introduction of a time out delay period
(5s) and correction trials. The timeout delay was triggered by an incorrect response selection (Simage/location coupling) and was paired to the house light turning on. Once the timeout delay
had elapsed the ITI was initiated, which was then followed by the reward magazine tray being
illuminated. At this point mice were required to enter and withdraw from the reward magazine
tray to start a correction trial. A response was required, as omissions were not a feature of this
task. Correction trials re-presented the S+ and S- image/location couplings presented in the
previous trial. This was repeated for each subsequent trial until the mouse correctly responded to
the S+ image/location coupling. Correction trial results did not contribute toward completion
criterion for the session. Completion criterion was defined as 36 trials completed within a single
60-minute session, for 45 days.

2.20 Primary Touchscreen Parameters
The ABET II touchscreen software automatically organizes and compiles rodent behavioural
responses into various metrics for subsequent performance evaluations and post-processing
quality control. The central metrics used to analyze behaviour are as follows:

Sessions/Trials to Criterion (Acquisition; PVD, 5-CSRTT): number of sessions/trials required by
an animal to reach the desired performance baselines (e.g., 80%) during training.

Accuracy (% Correct; PVD, dPAL, 5-CSRTT): the number of successful operant responses to
the S+ represented as a percentage.
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Correction Trials (PVD, dPAL): the number of trial re-presentations required by the animal
before a correct response to the S+ is emitted.

Breakpoint (PR): the peak number of responses elicited by an animal for a single food reinforcer
within the last trial successfully completed.

Omissions (5-CSRTT): the failure of an animal to elicit an operant response to the touchscreen
during the stimulus presentation and 5-second limited hold.

Perseverative Response (5-CSRTT, PRFR): the total number of operant responses elicited
following stimulus removal.

Correct Touch Latency (PVD, dPAL, 5-CSRTT, PRFR): the amount of elapsed time following a
stimulus presentation and a successful operant response to the S+.

Incorrect Touch Latency (PVD, dPAL, 5-CSRTT, PRFR): the amount of elapsed time following
a stimulus presentation and an incorrect operant response to the S-.

Reward Collection Latency (PVD, dPAL, 5-CSRTT, PRFR): the amount of elapsed time
following a successful operant response to the S+ and IR-beam detection of entry into the reward
magazine tray.

2.21 Cohorts and Behavioural Testing Schedule
Data has been obtained from two separate cohorts of the TDP-43Q331Klow mutant mouse line and
their littermate controls. Additionally, data has also been obtained from two separate cohort of
the TDP-43G348C mouse line and their littermate controls.
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Figure 2. Experimental design outlining the sequence of behavioural testing in TDP43Q331Klow and TDP-43G348C mutant mice.
2.22 Statistical Analyses
JASP stats version 0.13.1 (https://jasp-stats.org) and GraphPad PRISM version 8.4.3 (GraphPad
Software, Inc., San Diego, California) were used to conduct all statistical analyses. PVD, PAL,
5-CSRTT, PRFR and motor tests were analysed based on mean performance over sessions (10,
45, 2, 2; respectively). Between-group differences were evaluated with t-test or Welch’s t-test,
contingent on distribution of data. Repeated-measures data were analysed using two-way
repeated measures- (RM) analysis of variance (ANOVA) with significance set to p<0.05.
Violations of sphericity indicated by Mauchly’s test of sphericity were corrected with the
Greenhouse-Geisser correction. Homogeneity of variance was tested using Levene’s test. All
post-hoc tests carried out utilized either the Bonferroni correction or simple main effect analyses.
Data presented as mean ± standard error of measurement (SEM). Significance set to p<0.05. All
data were analyzed separately at 4-months, 8-months and 11-months of age.

3. Results
3.1 Motor Performance Battery: TDP-43Q331Klow Mice
Rodent motor performance was evaluated prior to cognitive testing and during maintenance
periods to identify any potential ALS-like motor deficits, and the possibility of such deficits
affecting performance during touchscreen tasks.
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Initially, we determined grip force in 4-month-old and 8-month old TDP-43Q331Klow mutant mice.
We found no difference in grip strength in 4 month-old TDP-43Q331Klow mutants compared with
littermate controls (Figure 3A; Welch’s t-test, t(18.82) = 0.654, p = 0.520). In contrast, in 8-monthold TDP-43Q331Klow mutants we observed a significantly reduced peak grip force strength when
compared to littermate controls. (Figure 3B; Welch’s t-test, t(40.36) = 3.385, p = 0.001).

Figure 3. TDP-43Q331Klow mutant mice 4-month and 8-month peak grip force performance. At 4months no significant differences in peak grip force were observed. At 8-months TDP43Q331Klow mutants had lower peak grip force strength compared to controls (het n=27, wt
n=18, **p<0.01).

Sustained motor performance was evaluated with wire hang tests in 4-month-old and 8-monthold TDP-43Q331Klow mutant mice. We could not detect any difference in performance in these two
ages for the TDP-43 mutant mice compared to controls (Figure 4A; trial 1: t(6.82) = 0.260, p =
0.801; trial 2: no statistical difference; identical values: trial 3: t(8) = 1.000, p = 0.346, Figure
4B; trial 1: t(8) = 1.000, p = 0.346; trial 2; t(8) = 1.000, p = 0.346; trial 3; t(6.82) = 0.260, p =
0.801).
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Figure 4. TDP-43Q331Klow mutant mice 4-month and 8-month wire hang performance. No
significant differences were observed at 4- or 8-months (het n=27, wt n=18).
To investigate overall movement, we used automated locomotor boxes (Janickova, Prado, et al.,
2017; Janickova, Rosborough, et al., 2017). No significant differences were detected in
locomotor activity in 4-month-old TDP-43Q331Klow mutant mice when compared to littermate
controls (Figure 5A; no main effect of genotype, F(1,22) = 0.029, p = 0.865; main effect of time,
F(4.18,92.03) = 18.832, p = 0.001; and no significant genotype and time interaction, F(4.18,92.03) =
0.410, p = 0.809). Similar results were obtained at 8 months of age (Figure 5B; no genotype
effect F(1,12) = 4.210, p = 0.063; no effect of time, F(11,132) = 0.780, p =0.660; and no significant
interaction between genotype and time F(11,132) = 1.033, p = 0.421). Interestingly, as observed
previously, mice under food restriction at 8 months of age did not habituate to the locomotor
boxes (Mels, 2018).

Figure 5. TDP-43Q331Klow mutant mice 4-month and 8-month locomotor behaviour.
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No significant differences were observed at 4- or 8-months. Mean locomotion in 5-minute
intervals over a sustained 60-minute testing period (het n=27, wt n=18).

3.2 Motor Performance Battery: TDP-43G348C Mice
We also determined grip force in 4-month-old and 8-month old TDP-43G348C mutant mice. We
observed no difference in grip strength in 4 month-old TDP-43G348C mutants compared with
littermate controls (Figure 6A; Welch’s t-test, t(24.85) = 1.078, p = 0.291). Interestingly, similar to
results obtained in TDP-43Q331Klow mutant mice, 8-month-old TDP-43G348C mutants presented
reduced peak grip force strength when compared to littermate controls. (Figure 6B; Welch’s ttest, t(22.57) = 2.625, p = 0.015).

Figure 6. TDP-43G348C mutant mice 4-month and 8-month peak grip force performance. At 4months no significant differences in peak grip force were observed. At 8-months TDP-43G348C
mutants had lower peak grip force strength compared to controls (het n=22, wt n=15, data are
mean ± SEM, *p<0.05).
We also looked to evaluate sustained motor performance in the TDP-43G348C mice at 4- and 8months-old. Motor performance appeared unaltered at these two ages for TDP-43G348C mutant
mice when compared to controls, similar to the results obtained with TDP-43Q331Klow (Figure
7A; trial 1: t(39.77) = 0.334, p = 0.739; trial 2: t(21) = 1.801, p = 0.086; trial 3: t(44.65) = 0.350, p =
0.727, Figure 7B; trial 1: t(34.69) = 0.354, p = 0.725; trial 2; t(14) = 1.467, p = 0.164; trial 3; t(21) =
1.000, p = 0.328).
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Figure 7. TDP-43G348C mutant mice 4-month and 8-month wire hang performance. No
significant differences were observed at 4- or 8-months (het n=22, wt n=15).

No significant differences were detected in locomotor activity in 4-month-old TDP-43Q331Klow
mutant mice when compared to littermate controls (Figure 8A; no main effect of genotype,
F(1,42) = 0.059, p = 0.810; main effect of time, F(5.05,212.47) = 3.387, p = 0.006; and no significant
genotype and time interaction, F(5.05,212.47) = 0.511, p = 0.770). Similar results were obtained at 8
months of age (Figure 8B; no genotype effect F(1,10) = 0.426, p = 0.529; no effect of time,
F(11,110) = 0.945, p =0.501; and no significant interaction between genotype and time F(11,110) =
0.611, p = 0.816). Again, mice under food restriction at 8 months of age did not habituate to the
locomotor boxes (Mels, 2018). Overall, motor performance in the two TDP-43 mouse lines
showed essentially similar results, with a decrease in grip strength in 8-month-old mice, without
any other gross change.
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Figure 8. TDP-43G348C mutant mice 4-month and 8-month locomotor behaviour. No significant
differences were observed at 4- or 8-months. Mean locomotion in 5-minute intervals over a
sustained 60-minute testing period (het n=22, wt n=15).

3.3 PVD Task Learning and Cognitive Flexibility in 4-month-old TDP-43Q331Klow
Learning and cognitive flexibility were assessed in TDP-43Q331Klow mutants for potential
FTD/ALS-related cognitive deficits using the PVD and reversal touchscreen test.
TDP-43Q331Klow mutants required more sessions to reach performance criterion in comparison to
their littermate controls (Figure 9A; Welch’s t-test, t(20.12) = 2.447, p = 0.023).

Once mice reached a stable performance, the contingency on the PVD task was reversed (Fig.
9B). TDP-43Q331Klow mutant mice made significantly more errors during reversal learning at 4months-old in comparison to littermate controls (Figure 9B; Main effect of genotype, F(1,14) =
8.456, p = 0.011; main effect of session, F(4.14,58.04) = 47.668, p = <0.001; no interaction effect
between genotype and session F(4.14,58.04) = 1.970, p = 0.109). Consistent with these results, TDP43Q331Klow mutants required significantly more correction trials in comparison to littermate
controls (Figure 9C; significant main effect of genotype F(1,15) = 7.735, p = 0.014; significant
main effect of session, F(3.92,58.83) = 24.092, p = <0.001; no interaction effect between genotype
and session, F(3.92,58.83) = 0.847, p = 0.499).
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Figure 9. TDP-43Q331Klow mutant mice 4-months, PVD task acquisition (A; learning), reversal
learning performance (B), and correction trials (C).TDP-43Q331Klow mutants required significantly
more sessions to acquire the task, had significantly lower accuracy during reversal learning, and
required significantly more correction trials (het n=12, wt n=9, data are mean ± SEM, *p<0.05,
**p<0.01).

We also analysed various latency measures in 4-month-old TDP-43Q331Klow mutants undergoing
PVD testing to gain insight into their motivation to perform the task. TDP-43Q331Klow mutants
needed marginally more time to collect reward following correct responses in comparison to
littermate controls (Figure 10A; significant main effect of genotype, F(1,18) = 6.042, p = 0.024;
significant main effect of session, F(2.44,43.92) = 3.368, p = 0.035; no interaction between genotype
and session, F(2.44,43.92) = 0.994, p = 0.392). When making correct responses TDP-43Q331Klow
mutant mice required significantly more time in contrast to littermate controls (Figure 10B;
significant main effect of genotype, F(1,18) = 6.977, p = 0.017, indicating on average TDP43Q331Klow mutant mice required more time for correct responses per session; significant main
effect of session, F(2.53,45.58) = 12.088, p = <0.001; There was no interaction effect between
genotype and session F(2.53,45.58) = 2.649, p = 0.069). We also assessed incorrect touch latencies
in TDP-43Q331Klow mutant mice and similar to the results of correct touch latency, TDP-43Q331Klow
mutant mice required significantly more time prior to emitting an incorrect response in
comparison to littermate controls in the first reversal tests, lowering their performance to that of
controls in the later stages of testing (Figure 10C; significant main effect of genotype, F(1,15) =
10.23, p = 0.006, indicating on average TDP-43Q331Klow mutant mice needed additional time to
emit an incorrect response per session; significant effect of session, F(5.44,81.73) = 5.777, p =
<0.001; no interaction effect between genotype and session F(5.44,81.73) = 1.820, p = 0.112).
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Figure 10. 4-month-old TDP-43Q331Klow mutant mice latency data. Reward collection latency
(A), correct touch latency (B) and incorrect touch latency (C). TDP-43Q331Klow mutants required
marginally more time to collect reward, significantly more time to initiate correct responses and
significantly more time to emit incorrect responses (het n=12, wt n=9, data are mean ± SEM,
*p<0.05, **p<0.01).

3.4. 4-month-old TDP-43G348C Learning and Cognitive Flexibility in the PVD Task
We performed similar PVD assays in TDP-43G348C mutants to determine whether there are
common PVD deficits that overlap between mouse models.
Similar to TDP-43Q331Klow mutant mice, TDP-43G348C mutants require more sessions to reach
performance criterion in comparison to their littermate controls (Figure 11A; Welch’s t-test,
t(22.09) = 2.077, p = 0.049).

We then tested for FTD/ALS-like impairments in cognitive flexibility in these mice. We reversed
the stimulus-reward contingency and found that TDP-43G348C mutant mice made significantly
more errors during reversal learning at 4-months-old in comparison to littermate controls (Figure
11B; significant main effect of genotype, F(1,18) = 6.235, p = 0.022; significant main effect of
session, F(3.79,68.28) = 39.11, p = <0.001; no interaction effect between genotype and session
F(3.79,68.28) = 1.023, p = 0.399). Throughout the reversal, particularly in later stages, 4-month-old
TDP-43G348C mutant mice did not significantly differ from littermate controls in the number of
required correction trials (Figure 11C; no genotype effect, F(1,18) = 2.280, p = 0.148; significant
main effect of session, F(3.74,67.39) = 18.341, p = <0.001a; no significant interaction detected
between genotype and session, F(3.74,67.39) = 0.983, p = 0.419.
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Figure 11. TDP-43G348C mutant mice 4-month, PVD task acquisition (A; learning) and reversal
learning performance (B) and correction trials (C). It was found that TDP-43G348C mutants
required significantly more sessions to acquire the task, had significantly lower accuracy during
reversal learning and exhibited a highly similar number of required correction trials (het n=14,
wt n=11, data are mean ± SEM, *p<0.05, **p<0.01).

We also sought to evaluate motivation of 4-month-old TDP-43G348C mice in the PVD task
through observed latencies as done similarly in the TDP-43Q331Klow mice. It was revealed that 4month-old TDP-43G348C mutant mice reward collection latencies did not significantly differ
compared to littermate controls (Figure 12A; no genotype effect, F(1,22) = 0.168, p = 0.686; no
effect of session F(2.47,54.44) = 2.678, p = 0.066; no. interaction effect between genotype and
session, F(2.47,54.44) = 0.495, p = 0.652). We continued latency evaluations with correct touch
latencies. It was revealed that TDP-43G348C mutant mice required significantly less time before
eliciting a correct response in contrast to littermate controls (Figure 12B; no effect of genotype,
F(1,23) = 0.011, p = 0.917; significant main effect of session, F(4.51,103.80) = 10.528, p = <0.001a;
significant interaction effect between genotype and session F(4.51,103.80) = 2.385, p = 0.049). This
interaction was explored with simple main effects revealing a significantly lower correct touch
latency at R10 during the reversal phase, p = 0.029. Incorrect touch latencies were also evaluated
in 4-month-old TDP-43G348C mutant mice. It was revealed that mutant mice did not significant
differ from littermate controls (Figure 12C; no effect of genotype, F(1,20) = 0.687, p = 0.417; no
effect of session, F(6.03,120.63) = 1.618, p = 0.147; no interaction effect between genotype and
session F(6.03,120.63) = 1.796, p = 0.105).
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Figure 12. TDP-43G348C mutant mice 4-month PVD task reward collection latency (A), correct
touch latency (B) and incorrect touch latency (C). No significant differences were observed in
reward collection latencies, correct touch latencies and incorrect touch latencies (het n=14, wt
n=11, data are mean ± SEM, *p<0.05).

To clearly visualize and compare the major similarities in performance from the PVD task in the
two TDP-43 mutant mouse lines we assembled a graph with the main findings (Figure 13;
significant main effect of genotype, F(3,32) = 5.590, p = 0.003; significant main effect of session,
F(4.89,156.57) = 96.827, p = <0.001; no interaction effect between genotype and session F(4.89,156.57)
= 1.241, p = 0.399). These findings highlight that both TDP-43Q331Klow and TDP-43G348C mutant
mouse lines exhibit highly similar deficits during acquisition, and their performance during
reversal learning also demonstrates very strong similarities.

Figure 13. Combined PVD task data from TDP-43Q331Klow and TDP-43G348C mutant mice
(Figures 9A-B; 14A-B). TDP-43Q331Klow and TDP-43G348C mutants display a similar pattern of
deficits during task acquisition and during the reversal learning phase.
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3.5 dPAL Visuospatial Memory Performance of 8-month-old TDP-43Q331Klow
Visuospatial memory performance was assessed in TDP-43Q331Klow mutants to determine
potential FTD/ALS-related cognitive deficits using the dPAL task.

Given the deficits in visual discrimination and reversal observed in both TDP-43 mice we further
tested for learning and memory impairments using the PAL task. Both mouse lines were tested in
PAL after their PVD testing. No significant differences in accuracy were observed in 8-month
old TDP-43Q331Klow mutant mice compared to littermate controls (Figure 14A; no effect of
genotype, F(1,25) = 0.759, p = 0.392; significant main effect of week, F(4.92,123.01) = 93.396, p =
<0.001; No significant interaction effect between genotype and session F(4.92,123.01) = 1.38, p =
0.235). Similar to PVD we evaluated latency data as a proxy for motivation in TDP-43Q331Klow
mice. Reward collection latencies were evaluated in 8-month-old TDP-43Q331Klow mutant mice
revealing no significant differences from littermate controls (Figure 14B; significant main effect
of genotype, F(1,25) = 6.201, p = 0.020; significant main effect of week, F(3.42,85.71) = 2.851, p =
0.036; no interaction effect between genotype and week, F(3.42,85.71) = 1.287, p = 0.283).
Likewise, in the PAL test we found no significant differences when mutants were compared to
littermate controls for correct touch latency (Figure 14C; no effect of genotype, F(1,25) = 4.070, p
= 0.054; significant main effect of week, F(2.00,50.06) = 8.704, p = <0.001; no significant
interaction effect between genotype and session F(2.00,50.06) = 1.745, p = 0.185). Similarly, TDP43Q331Klow mutant mice revealed no significant differences from littermate controls in incorrect
touch latencies (Figure 14D; significant main effect of genotype, F(1,125) = 4.262, p = 0.049; no
effect of week, F(1.81,45.30) = 2.237, p = 0.123; no significant interaction effect between genotype
and session F(1.81,45.30) = 1.129, p = 0.328).
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Figure 14. TDP-43Q331Klow mutant mice 8-month PAL task accuracy (A), reward collection
latency (B), correct touch latency (C) and incorrect touch latency (D). No significant differences
were observed in any of the dPAL measures (het n=12, wt n=9).

3.6 dPAL Visuospatial Memory Performance of 8-month-old TDP-43G348C
In similar fashion to TDP-43Q331Klow mice, PVD assessments were subsequently followed up
with visuospatial memory evaluations in TDP-43G348C mice using the dPAL task.
Accuracy was evaluated in 8-month old TDP-43G348C mutant mice during the dPAL task
revealing no significant differences from littermate controls (Figure 15A; no effect of genotype,
F(1,23) = 0.852, p = 0.366; significant main effect of week, F(4.16,95.76) = 77.50, p = <0.001; no
interaction effect between genotype and session F(4.16,95.76) = 0.388, p = 0.824). Reward
collection latencies were also evaluated in 8-month-old TDP-43G348C mutant mice. No significant
differences were detected from comparisons to littermate controls (Figure 15B; no effect of
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genotype, F(1,23) = 2.877, p = 0.103; no effect of week, F(1.26,29) = 2.598, p = 0.111; No interaction
effect between genotype and week, F(1.26,29) = 2.512 p = 0.117). Similarly, correct touch latencies
were assessed in 8-month old TDP-43G348C mutant mice and no significant differences were
revealed when mutants were contrasted to littermate controls (Figure 15C; no effect of
genotype, F(1,23) = 0.665, p = 0.423; significant main effect of week, F(1.75,40.25) = 16.893, p =
<0.001; no significant interaction effect between genotype and session F(1.75,40.25) = 1.508, p =
234). The last latency measure assessed in 8-month-old TDP-43G348C mutant mice was incorrect
touch latencies. No significant differences were detected from comparisons to littermate controls
(Figure 18D; no effect of genotype, F(1,23) = 0.492, p = 0.490; significant main effect of week,
F(1.95,44.95) = 8.947, p = 0.001; No interaction effect between genotype and session F(1.95,44.95) =
1.585, p = 0.217).

Figure 15. TDP-43G348C mutant mice 8-month PAL task accuracy (A), reward collection latency
(B), correct touch latency (C) and incorrect touch latency (D). No significant differences were
observed among dPAL measures (het n=14, wt n=11).

53
3.7 5-CSRTT Probe of Attention Performance in 4-month-old TDP-43Q331Klow
To further investigate executive function, we tested the TDP-43 mouse lines in a test of attention,
5-CSRTT.
TDP-43Q331Klow mutant mice performed as well as control mice during 5-CSRTT training at 4
and 2 s (Figure 16A; Welch’s t-test, t(23.72) = 0.1743, p = 0.863, Figure 16B; Welch’s t-test,
t(14.86) = 0.2279, p = 0.822).

Figure 16. TDP-43Q331Klow mutant mice 4-month 5-CSRTT trials to acquisition 4- and 2-seconds.
No significant differences were observed (het n=15, wt n=9).

To investigate attentional demand 4-month-old mice were tested in probe trials (1.5, 1.0, 0.8 and
0.6s). Surprisingly, mutants differ significantly from littermate controls displaying higher
accuracy (Figure 17A; main effect of genotype was significant, F(1,21) = 5.449, p = 0.030; a
significant main effect of stimulus duration, F(3,63) = 24.074, p = <0.001, indicating significantly
higher accuracy at longer stimulus durations; no interaction effect between genotype and
stimulus duration F(3,63) = 0.422, p = 0.738). Omissions were also recorded and we found a small
but significant effect of increased omissions at 0.6s (Figure 17B; no effect of genotype, F(1,21) =
1.319, p = 0.264; significant main effect of stimulus duration, F(3,63) = 43.222, p = <0.001,
indicating significantly higher omissions at longer stimulus durations; significant interaction
effect between genotype and stimulus duration, F(3,63) = 3.299, p = 0.026, This interaction was
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explored with simple main effects which revealed significantly higher omissions during the 0.6second stimulus duration, p = 0.019).

Figure 17. TDP-43Q331Klow mutant mice 4-month 5-CSRTT accuracy (A) and omission (B). It
was found that TDP-43Q331Klow mutants exhibited significantly higher accuracy and omissions in
comparison to controls (het n=15, wt n=9, data are mean ± SEM, *<p=0.05, **<p=0.01).
In line with other touchscreen tasks, various latency metrics were evaluated for insight into TDP43Q331Klow motivation. Reward collection latencies were investigated in 4-month-old TDP43Q331Klow mutant mice. It was found that mutants did not differ significantly from littermate
controls (Figure 18A; no effect of genotype, F(1,21) = 2.367, p = 0.139; no effect of stimulus
duration, F(2.03,42.80) = 1.496, p = 0.235; no significant interaction effect between genotype and
stimulus duration, F(2.03,42.80) = 2.433, p = 0.099). Similarly, correct touch latencies were
evaluated in 4-month-old TDP-43Q331Klow mutant mice. It was revealed that mutant mice did not
significantly differ from littermate controls (Figure 18B; no effect of genotype, F(1,21) = 0.509, p
= 0.483; significant main effect of stimulus duration, F(1.95,41.00) = 32.789, p = <0.001; No
interaction effect between genotype and stimulus duration, F(1.95,41.00) = 0.489, p = 0.612). The
final 5-CSRTT latency metric assessed was incorrect touch latencies in 4-month-old TDP43Q331Klow mutant mice. It was found that mutant mice did not significantly differ from littermate
controls (Figure 18C; No genotype effect, F(1,21) = 0.215, p = 0.648; no stimulus duration effect,
F(3,63) = 0.693, p = 0.560; no interaction effect, F(3,63) = 0.904, p = 0.444).
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Figure 18. TDP-43Q331Klow mutant mice 4-month 5-CSRTT reward collection latency (A) correct
touch latency (B) and incorrect touch latency (C) No significant differences were observed (het
n=15, wt n=9).

A behavioural component of interest during 5-CSRTT touchscreen testing is the actions
surrounding the performance of responses to the touchscreens. Accordingly, we looked to
evaluate premature and perseverative responses. It was found that 4-month-old TDP-43Q331Klow
mutant mice did not significantly differ from littermate controls in the number of premature
responses emitted (Figure 19A; no effect of genotype, F(1,19) = 0.298, p = 0.591; significant main
effect of stimulus duration, F(3,57) = 3.177, p = 0.031; no interaction effect between genotype and
stimulus duration, F(3,57) = 0.942, p = 0.426). Perseverative post-correct responses were also
evaluated in 4-month-old TDP-43Q331Klow mutant mice. It was found that mutants exhibited
significantly higher perseverative responses when compared to littermate controls (Figure 19B;
no effect of genotype, F(1,20) = 1.205, p = 0.285; no effect of stimulus duration, F(3,60) = 0.531, p
= 0.663; significant interaction effect between genotype and stimulus duration, F(3,60) = 4.442, p
= 0.007). This interaction was explored with simple main effects revealing significantly higher
TDP-43Q331Klow mutant perseverative post-correct responses during the 1.0-second stimulus
duration, p = 0.017. Similarly, perseverative post-incorrect responses were also evaluated in 4month-old TDP-43Q331Klow mutant mice. It was revealed that mutants did not differ from
littermate controls with respect to perseverative responses (Figure 19C; No genotype effects,
F(1,5) = 0.235, p = 0.649; no effect of stimulus duration, F(1.03,5.15) = 0.454, p = 0.535; No
interaction effect between genotype and stimulus duration, F(1.03,5.15) = 0.536, p = 0.501).
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Figure 19. TDP-43Q331Klow mutant mice 4-month 5-CSRTT premature responses (A),
perseverative post-correct responses (B) and perseverative post-incorrect responses (C) No
significant differences were observed among measures (het n=15, wt n=9, data are mean ± SEM,
*<p=0.05).

3.8 5-CSRTT Probe of Attention Performance in 8-month-old TDP-43Q331Klow
To test for age-dependent effects of attention, we tested the TDP-43 mouse lines at a second time
point in the 5-CSRTT.
TDP-43Q331Klow mutant mice show progressive pathological changes (Arnold et al., 2013a).
Accordingly, we wanted to explore whether older TDP-43 mice would have attentional
performance at least consistent with 4-month-old TDP-43Q331K mutant mice, or alternatively
worse performance. To evaluate accuracy 8-month-old TDP-43Q331Klow mutant mice were
investigated. It was found that mutant mice significantly differ from littermate controls
displaying higher accuracy (Figure 20A; no effect of genotype, F(1,22) = 2.628, p = 0.119;
significant main effect of stimulus duration, F(3,66) = 32.76, p = <0.001, indicating significantly
higher accuracy at longer stimulus durations; no significant interaction effect F(3,66) = 1.031, p =
0.385). We also looked to revaluate omissions in 8-month-old TDP-43Q331Klow mutant mice. It
was found that mutants significantly differed from littermate controls with higher omission
behaviour (Figure 20B; no effect of genotype, F(1,22) = 0.059, p = 0.811; significant main effect
of stimulus duration, F(3,66) = 49.88, p = <0.001, indicating significantly higher omissions at
longer stimulus durations; significant interaction effect between genotype and stimulus duration,
F(3,66) = 4.414, p = 0.009). This interaction was explored with simple main effects which revealed
significantly higher omissions during the 0.6-second stimulus duration, p = 0.019.
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Figure 20. TDP-43Q331Klow mutant mice 8-month 5-CSRTT accuracy (A) and omissions (B). It
was found that TDP-43Q331Klow mutants exhibited significantly higher accuracy in comparison to
controls. Additionally, significantly higher omissions when compared to controls (het n=15, wt
n=9, data are mean ± SEM, *<p=0.05, **<p=0.01).

Here we looked to re-evaluate latency measures in 8-month-old TDP-43Q331Klow mice to observe
any potential changes due to age-dependent TDP-43 mutant disease progression. Reward
collection latencies were evaluated in 8-month-old TDP-43Q331Klow mutant mice. It was found
that mutant reward collection latencies did not significantly differ from littermate controls
(Figure 21A; no effect of genotype, F(1,22) = 0.038, p = 0.847; no effect of stimulus duration,
F(1.32,24.91) = 0.843, p = 0.381; no significant interaction effect, F(1.32,24.91) = 0.219, p = 0.674).
Similarly, correct touch latencies were also evaluated in 8-month-old TDP-43Q331Klow mutant
mice. It was revealed that mutants did not exhibit any significant differences from littermate
controls (Figure 21B; no effect of genotype, F(1,21) = 0.874, p = 0.361; significant effect of
stimulus duration, F(3,63) = 22.86, p = <0.001; No interaction effect, F(3,63) = 2.138, p = 0.104).
Lastly incorrect touch latencies were evaluated in 8-month-old TDP-43Q331Klow mutant mice. It
was revealed that mutant incorrect touch latencies did not significantly differ from littermate
controls (Figure 21C; No genotype effect, F(1,22) = 0.947, p = 0.341; no stimulus duration effect ,
F(3,66) = 0.485, p = 0.694; No interaction effect, F(3,66) = 0.943, p = 0.425).
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Figure 21. TDP-43Q331Klow mutant mice 8-month 5-CSRTT reward collection latency. No
significant differences were observed (het n=15, wt n=9).

All behavioural response aspects surrounding the performance of responses to the touchscreens
were re-evaluated again to observe any age-dependent effects. Premature responses of 8-monthold TDP-43Q331Klow mutant mice were investigated. It was revealed that mutants’ premature
responses did not differ significantly from littermate controls (Figure 22A; no genotype effect,
F(1,22) = 2.188, p = 0.153; no stimulus duration effect, F(2.04,44.92) = 2.253, p = 0.116; no
significant interaction effect duration, F(3,24) = 0.111, p = 0.899). Similarly, perseverative postcorrect responses in 8-month-old TDP-43Q331Klow mutant mice were investigated. It was revealed
that mutant perseverative responses did not differ significantly from littermate controls (Figure
22B; no effect of genotype, F(1,22) = 6.142, p = 0.980; no effect of stimulus duration, F(3,66) =
1.719, p = 0.172; no interaction effect, F(3,66) = 1.801, p = 0.156). To assess perseverative postincorrect responses 8-month-old TDP-43Q331Klow mutant mice were investigated. It was revealed
that mutant mice did not differ from littermate controls with respect to perseverative responses
(Figure 22C; no genotype effect, F(1,22) = 2.498, p = 0.128; no effect of stimulus duration,
F(1.59,35.16) = 0.751, p = 0.452; no interaction effect, F(1.59,35.16) = 1.074, p = 0.339).
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Figure 22. TDP-43Q331Klow mutant mice 8-month 5-CSRTT premature responses (A),
perseverative post-correct responses (B) and perseverative post-incorrect (C). No significant
differences were observed (het n=15, wt n=9).

3.9 5-CSRTT Probe of Attention Performance in 4-month-old TDP-43G348C
In line with using the same tasks to explore cognitive aspects in each mutant TDP-43 mouse line,
we looked to re-evaluate TDP-43G348C mice with the 5-CSRTT test of attention to determine
potential changes resulting in age-dependent progression of TDP-43 pathology (Swarup et al.,
2011).
Similarly, acquisition was also evaluated in 4-month-old TDP-43G348C mutant mice. It was found
that mutants did not differ significantly from littermate controls with respect to sessions required
to reach performance criterion with 4-second (Figure 23A; Welch’s t-test, t(4.43) = 0.0928, p =
0.930), or 2-second stimulus durations (Figure 23B; Welch’s t-test, t(4.12) = 0.5573, p = 0.606).

Figure 23. TDP-43G348C mutant mice 4-month 5-CSRTT trials to acquisition 4- and 2-seconds.
No significant differences were observed (het n=8, wt n=4).
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Again, with the 5-CSRTT we looked to evaluate attentional demands in the TDP-43G348C mutant
mice, and in the same manner as the TDP-43Q331Klow mice. To assess accuracy 4-month-old TDP43G348C mutant mice were investigated. It was revealed that mutants did not significantly differ
from littermate controls in task accuracy (Figure 24A; no effect of genotype, F(1,10) = 3.050, p =
0.111; main effect of stimulus duration, F(3,30) = 15.699, p = <0.001; no interaction effect, F(3,30)
= 0.585, p = 0.629). Omissions were also evaluated in 4-month-old TDP-43G348C mutant mice. It
was found that mutants did not differ significantly from littermate controls in omission behaviour
(Figure 24B; no genotype effect, F(1,10) = 3.099, p = 0.109; significant main effect of stimulus
duration, F(3,30) = 23.151, p = <0.001; no interaction effect, F(3,30) = 0.933, p = 0.437).

Figure 24. TDP-43G348C mutant mice 4-month 5-CSRTT accuracy (A) and omissions (B). No
significant differences were observed (het n=8, wt n=4).

As a way to assess motivation in TDP-43G348C mutant mice as with the TDP-43Q331Klow mutants
we looked to evaluate various latency measures in the 5-CSRTT. Reward collection latencies
with 4-month-old TDP-43G348C mutant mice were assessed. It was found that mutant reward
collection latencies did not significantly differ from littermate controls (Figure 25A; no effect of
genotype, F(1,10) = 2.663, p = 0.134; no effect of stimulus duration, F(1.19,11.98) = 1.501, p =0.251;
no significant interaction effect, F(1.19,11.98) = 1.788, p = 0.209). The resulting correct touch
latencies of 4-month-old TDP-43G348C mutant mice were similarly evaluated. It was revealed that
mutants did not significantly differ from littermate controls (Figure 25B; no effect genotype,
F(1,10) = 1.049, p = 0.330; significant effect of stimulus duration, F(1.95,19.56) = 5.672, p = 0.012; no
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interaction effect, F(1.95,19.56) = 0.129, p = 0.876). Incorrect touch latencies of 4-month-old TDP43G348C mutant mice were also investigated. It was found that mutant incorrect touch latencies
did not significantly differ from littermate controls (Figure 25C; no genotype effects, F(1,10) =
0.744, p = .0409; no stimulus duration effect, F(3,30) = 1.192, p = 0.329; no interaction effect,
F(3,30) = 1.069, p = 0.377).

Figure 25. TDP-43G348C mutant mice 4-month 5-CSRTT reward collection latency (A), correct
touch latency (B) and incorrect touch latency (C). No significant differences were observed (het
n=8, wt n=4).

Maintaining consistency, TDP-43G348C mutant mice were also evaluated for possible abnormal
behavioural responses surrounding the performance of responses to the touchscreen. Premature
responses were evaluated in 4-month-old TDP-43G348C mutant mice. It was found that mutant
premature responses did not differ significantly from littermate controls (Figure 26A; no
genotype effect, F(1,8) = 0.164, p = 0.696; no stimulus duration effect, F(3,24) = 0.029, p = 0.993;
no significant interaction effect, F(3,24) = 2.093, p = 0.128). Similarly, perseverative post-correct
responses were assessed in 4-month-old TDP-43G348C mutant mice. It was found that mutant
perseverative responses did not differ significantly from littermate controls (Figure 26B; no
effect of genotype, F(1,10) = 0.251, p = 0.627; no effect of stimulus duration, F(3,30) = 1.769, p =
0.174; no interaction effect, F(3,30) = 6.273, p = 0.835). The last among response data was
perseverative post-incorrect responses. 4-month-old TDP-43G348C mutant mice did not differ
significantly from littermate controls with respect to perseverative responses (Figure 26C; no
genotype effect, F(1,10) = 1.232, p = 0.293; significant effect of stimulus duration, F(3,30) = 4.700,
p = 0.008; no interaction effect, F(3,30) = 0.976, p = 0.417).
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Figure 26. TDP-43G348C mutant mice 4-month 5-CSRTT premature responses (A),
perseverative post-correct responses (B) and perseverative post-incorrect responses (C). No
significant differences were observed (het n=8, wt n=4).

3.10 5-CSRTT Probe of Attention Performance in 8-month-old TDP-43G348C
The TDP-43G348C mutant mice were re-evaluated in similar fashion to the TDP-43Q331Klow
mice to assess progress age-dependent effects of TDP-43 altering cognitive performance
observed in 4-month-old mice.
The accuracy of 8-month-old TDP-43G348C mutant mice were the first to be re-investigated. It
was found that mutants did not significantly differ from littermate controls in task accuracy
(Figure 27A; no effect of genotype, F(1,6) = 1.665, p = 0.224; significant main effect of stimulus
duration, F(3,18) = 10.129, p = <0.001; no interaction effect F(3,18) = 1.436, p = 0.265). Similarly,
omission behaviour was also re-investigated in 8-month-old TDP-43G348C mutant mice. It was
found that omission behaviour significantly differed from littermate controls (Figure 27B;
significant main effect of genotype, F(1,6) = 10.796, p = 0.017; significant main effect of stimulus
duration, F(3,18) = 5.693, p = 0.006, indicating increased omissions during longer stimulus
durations; no interaction effect, F(3,18) = 0.956, p = 0.435).
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Figure 27. TDP-43G348C mutant mice 8-month 5-CSRTT accuracy. No significant differences
were observed (het n=8, wt n=4, data are mean ± SEM, *<p=0.05).

We also looked to re-evaluate motivation of 8-month-old TDP-43G348C mutant mice by observing
latencies measures as done with the TDP-43Q331Klow mice. Reward collection latency behaviours
were evaluated in 8-month-old TDP-43G348C mutant mice. It was found that mutant reward
collection latencies did not significant differ from littermate controls (Figure 28A; no effect of
genotype, F(1,6) = 0.451, p = 0.527; no effect of stimulus duration, F(1.2,7.58) = 0.190, p = 0.731; no
significant interaction effect, F(1.26,7.58) = 0.595, p = 0.502). Correct touch latencies were also reevaluated in 8-month-old TDP-43G348C mutant mice. It was revealed that mutants significantly
differed from littermate controls (Figure 28B; no effect genotype, F(1,6) = 3.660, p = 0.104;
significant effect of stimulus duration, F(3,18) = 23.499, p =<0.001, indicating higher correct
touch latencies during longer stimulus durations; significant interaction effect observed between
genotype and stimulus duration, F(3,18) = 10.194, p =<0.001). This interaction was explored with
simple main effects, which revealed mutant mice exhibited significantly higher correct touch
latencies during 1.5- and 1.0-second stimulus durations, p = 0.019 and p = 0.020 respectively. In
similar fashion, to assess incorrect touch latencies 8-month-old TDP-43G348C mutant mice were
re-evaluated. It was found that mutant incorrect touch latencies differed significantly from
littermate controls (Figure 28C; significant effect of genotype, F(1,6) = 6.503, p = 0.043,
indicating higher TDP-43G348C mutant incorrect touch latencies on average per session; no effect
of stimulus duration, F(3,18) = 2.557, p = 0.087; no interaction effect, F(3,18) = 0.820, p = 0.500).
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Figure 28. TDP-43G348C mutant mice 8-month 5-CSRTT reward collection latency (A) correct
touch latency (B) and incorrect touch latency (C). No significant differences were observed for
reward collection latency. Both correct touch- and incorrect touch latencies were significantly
different from control (het n=8, wt n=4, data are mean ± SEM, *<p=0.05).

We also wanted to investigate any potential changes caused by age-dependent progression of
TDP-43 in behavioural response aspects surrounding the performance of responses to
touchscreens in TDP-43G348C mutant mice. The first latency measure to be re-assessed was
premature responses of 8-month-old TDP-43G348C mutant mice. It was found that mutant
premature responses did not differ significantly from littermate controls (Figure 29A: no
genotype effect, F(1,6) = 0.559, p = 0.483; no stimulus duration effect, F(3,18) = 0.027, p = 0.994;
no significant interaction effect, F(3,18) = 0.730, p = 0.547). Similarly, perseverative post-correct
responses of 8-month-old TDP-43G348C mutant mice were re-evaluated. It was found that mutant
perseverative responses did not differ significantly from littermate controls (Figure 29B; no
effect of genotype, F(1,6) = 1.568, p = 0.257; no effect of stimulus duration, F(3,18) = 2.830, p =
0.068; no interaction effect, F(3,18) = 3.133, p = 0.051). Re-assessment of perseverative postincorrect responses in 8-month-old TDP-43G348C mutant mice revealed that mutants did not
significantly differ from littermate controls with respect to perseverative responses (Figure 29C;
no genotype effect, F(1,6) = 0.167, p = 0.697; no stimulus duration effect, F(1.14,6.87) = 2.804, p =
0.138; no interaction effect, F(1.14,6.876) = 0.606, p = 0.484).
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Figure 29. TDP-43G348C mutant mice 8-month 5-CSRTT premature responses (A),
perseverative post-correct responses (B) and perseverative post-incorrect responses (C). No
significant differences were observed (het n=8, wt n=4).

3.11 11-month-old TDP-43Q331Klow Probe of Motivation Performance in PRFR
We looked to evaluate FTD/ALS-related motivation deficits in TDP-43 mutant mice as a follow
up to previous experiments. The PRFR task is designed specifically to evaluate aspects of
motivation. Progressive ratio and fixed ratio data were analyzed separately but are represented
together graphically in some cases.

The primary metric used to assess motivation is breakpoint. Fixed-ratio breakpoints were
explored in 11-month-old TDP-43Q331Klow mutant mice. It was found that mutants did not differ
significantly from littermate controls in breakpoints (Figure 30A; FR1, ns, identical values; FR2,
ns, identical values; FR3, ns, identical values; FR5, Welch’s t-test, t(8) = 1.000, p = 0.346).
Progressive-ratio breakpoints were also evaluated in 11-month-old TDP-43Q331Klow mutant mice.
It was revealed that mutants did not differ significantly from littermate controls (Figure 30B; no
effect of genotype, F(1,20) = 0.038, p = 0.848; no effect of work requirement, F(2,40) = 0.133, p =
0.876; no interaction effect, F(2,40) = 0.100, p = 0.905).

66

Figure 30. TDP-43Q331Klow mutant mice 11-month fixed-ratio breakpoint (A) and progressiveratio breakpoint (B). No significant differences were observed (het n=13, wt n=9).

We also looked to evaluate target touches in TDP-43 mutant mice to observe exactly how many
responses were elicited within a given PRFR schedule. Fixed ratio target touches were assessed
in 11-month-old TDP-43Q331Klow mutant mice. It was revealed that mutants did not differ
significantly from littermate controls (Figure 31; FR1, ns, identical values; FR2, ns, identical
values; FR3, ns, identical values; FR5, Welch’s t-test, t(8) = 1.000, p = 0.346). Similarly,
progressive ratio target touches were also explored in 11-month-old TDP-43Q331Klow mutant
mice. It was revealed that mutants did not differ significantly from littermate controls (Figure
31; no genotype effect, F(1,20) = 0.002, p = 0969; significant effect of work requirement, F(2,40) =
23.094, p = <0.001; no interaction effect, F(2,40) = 0.170, p = 0.844).

Figure 31. TDP-43Q331Klow mutant mice 11-month progressive- and fixed-ratio target touches.
No significant differences were observed (het n=13, wt n=9).
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We also evaluated trials completed, another measure of how much work animals are willing to
expend. Evaluation of trials completed in 11-month-old TDP-43Q331Klow mutant mice revealed
that mutants did not significantly differ from littermate controls (Figure 32; FR1, ns, identical
values; FR2, ns, identical values; FR3, ns, identical values; FR5, Welch’s t-test, t(8) = 1.000, p =
0.346). Similarly, we then explored progressive ratio trials completed in 11-month-old TDP43Q331Klow mutant mice. It was revealed that mutant did not differ significantly from littermate
controls (Figure 32; no genotype effect, F(1,20) = 0.080, p = 0.780; significant effect of work
requirement, F(2,40) = 188.185, p = <0.001; no interaction effect, F(2,40) = 1.308, p = 0.282).

Figure 32. TDP-43Q331Klow mutant mice 11-month progressive- and fixed-ratio trials
completed. No significant differences were observed (het n=13, wt n=9).

We then looked to measure response latency as completed in other tasks, however this time in a
task dedicated to evaluating motivation. Assessment of fixed ratio reward collection latency in
11-month-old TDP-43Q331Klow mutant mice revealed that mutants differed significantly from
littermate controls (Figure 33; FR1, Welch’s t-test, t(6.27) = 2.086, p = 0.080; FR2, Welch’s t-test,
t(1.05) = 0.324, p = 0.797; FR3, Welch’s t-test, t(7.69) = 2.694, p = 0.028; FR5, Welch’s t-test, t(12.13)
= 0.379, p = 0.797). Progressive ratio reward collection latencies were also evaluated in 11month-old TDP-43Q331Klow mutant mice. It was found that mutants did not differ significantly
from littermate controls (Figure 33; no genotype effect, F(1,20) = 0.0065, p = 0.801; no effect of
work requirement, F(2,40) = 1.118, p = 0.337; no interaction effect, F(2,40) = 0.476, p = 0.625).
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Figure 33. TDP-43Q331Klow mutant mice 11-month progressive- and fixed-ratio reward
collection latency. TDP-43Q331Klow mutants exhibited significantly longer delays to reward
collection during fixed ratio testing (het n=13, wt n=9, data are mean ± SEM, *<p=0.05).

To further assess aspects of motivation beyond outright breakpoints we looked to evaluate
mutant TDP-43 mice with another distinct measure, post-reinforcement pause. Longer postreinforcement pauses indicate a possible decrease in motivation. 11-month-old TDP-43Q331Klow
mutant mice exhibited significantly shorter pauses when compared with littermate controls
(Figure 34; no genotype effect, F(1,20) = 1.258, p = 0.275; no work requirement effect, F(1.53,30.76)
= 1.202, p = 0.304; significant interaction effect, F(1.53,30.76) = 4.292, p = 0.031). This interaction
was explored with simple main effects, which indicated mutant mice exhibited significantly
shorter delays in the initiation of subsequent trials during the PR12 schedule, p=0.031.
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Figure 34. TDP-43Q331Klow mutant mice 11-month progressive-ratio post reinforcement
pause. TDP-43Q331Klow mutants exhibited significantly shorter post reinforcement pause
delays (het n=13, wt n=9, data are mean ± SEM, *<p=0.05).
3.12 11-month-old TDP-43G348C Probe of Motivation Performance in PRFR
To maintain consistency and further evaluate age-dependent effects of TDP-43 pathology on
aspects of motivation, TDP-43G348C mutants were also evaluated with the PRFR task.
The main metric to evaluate motivation in the PRFR task was also used to evaluate TDP-43G348C
mutants. Assessment of fixed-ratio breakpoints in 11-month-old TDP-43G348C mutant mice
revealed that mutants did not differ significantly from littermate controls in measured
breakpoints (Figure 35A; FR1, ns, identical values; FR2, ns, identical values; FR3, ns, identical
values; FR5, ns, identical values). Similarly, progressive-ratio breakpoints were evaluated in 11month-old TDP-43G348C mutant mice. It was revealed that mutants did not differ significantly
from littermate controls (Figure 35B; no effect of genotype, F(1,10) = 7.097, p = 0.979; no effect
of work requirement, F(2,20) = 2.219, p = 0.135; no interaction effect, F(2,20) = 0.421, p = 0.662).
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Figure 35. TDP-43G348C mutant mice 11-month progressive-ratio breakpoint. No significant
differences were observed (het n=8, wt n=4).

Target touches were also investigated as an alternative measure of motivation. Assessment of
fixed ratio target touches 11-month-old TDP-43G348C mutant mice revealed that mutants did not
differ significantly from littermate controls (Figure 36; FR1, ns, identical values; FR2, ns,
identical values; FR3, ns, identical values; FR5, ns, identical values). Furthermore, exploration of
target touches in 11-month-old TDP-43 G348C mutant mice did not reveal any significant
differences from littermate controls (Figure 36; no genotype effect, F(1,10) = 3.553, p = 0.985;
significant effect of work requirement, F(2,20) = 7.236, p = <0.004; no interaction effect, F(2,20) =
0.620, p = 0.548).

Figure 36. TDP-43G348C mutant mice 11-month progressive- and fixed-ratio target touches. No
significant differences were observed (het n=8, wt n=4).
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In similar fashion to 11-month-old TDP-43Q331Klow mice, we explored fixed ratio trials completed
in 11-month-old TDP-43G348C mutant mice. It was found that mutants did not differ significantly
from littermate controls (Figure 37; FR1, ns, identical values; FR2, ns, identical values; FR3, ns,
identical values; FR5, ns, identical values). This was followed up with exploration of progressive
ratio trials completed in 11-month-old TDP-43G348C mutant mice. It was found that mutants do
not differ significantly from littermate controls (Figure 37; no genotype effect, F(1,10) = 0.003, p
= 0.961; significant effect of work requirement, F(2,20) = 71.53, p = <0.001; no interaction effect,
F(2,20) = 0.343, p = 0.714).

Figure 37. TDP-43G348C mutant mice 11-month progressive- and fixed-ratio trials completed.
No significant differences were observed (het n=8, wt n=4).

Various latency measures were used to evaluated TDP-43G348C mutant mice in the dedicated
PRFR task, as was done with the TDP-43Q331Klow mice. Assessment of 11-month-old TDP43G348C revealed that mutants did not differ significantly from littermate controls (Figure 38;
FR1, Welch’s t-test, t(3.30) = 1.224, p = 0.300, p = 0.080; FR2, Welch’s t-test, t(2.90) = 0.298, p =
0.785; FR3, Welch’s t-test, t(2.04) = 1.053, p = 0.400; FR5, Welch’s t-test, t(7.99) = 1.246, p =
0.247). Furthermore, reward collection latencies from 11-month-old TDP-43G348C mutant mice
were evaluated. It was found that mutants did not significantly differ from littermate controls
(Figure 38; no genotype effect, F(1,10) = 0.110, p = 0.747; no work requirement effect, F(1.32,13.27)
= 0.680, p = 0.465; no interaction effect, F(1.32,13.27) = 0.331, p = 0.637).
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Figure 38. TDP-43G348C mutant mice 11-month progressive- and fixed-ratio reward collection
latency. No significant differences were observed (het n=8, wt n=4).

The last measure evaluated was post reinforcement pause. Evaluations in 11-month-old TDP43G348C mutant mice revealed that mutants did not differ significantly when compared with
littermate controls (Figure 39; no genotype effect, F(1,10) = 0.497, p = 0.497; No work
requirement effect was observed, F(2,20) = 0.253, p = 0.779. no interaction effect, F(2,20) = 1.511, p
= 0.245).

Figure 39. TDP-43G348C mutant mice 11-month progressive-ratio post reinforcement pause. No
significant differences were observed from control (het n=13, wt n=9).
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Figure 40. Overview of TDP-43Q331Klow and TDP-43G348C mutant mouse deficits across all
evaluation time points.
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4. Discussion
In the present study I assessed executive function in FTD/ALS-relevant male TDP-43Q331Klow and
-G348C

transgenic mice using automated touchscreens. Cognitive impairments were revealed in 4-

month-old and 8-month-old TDP-43Q331Klow and -G348C mutants. The cognitive impairments
detected in 4-month-old mice manifested before FTD/ALS-related motor dysfunction. This
pattern of results is very similar to observations in human FTD/ALS. Together, these findings
outline the usefulness of TDP-43 mutant mouse models in combination with automated
touchscreens.
4.1 Age-Dependent Motor Performance Deficits in TDP-43 Mutant Mice
In both TDP-43Q331Klow and TDP-43G348C mutant mice, motor performance remained largely
spared, although an age-dependent deficit in peak grip force strength was revealed at 8-months
of age. This finding is consistent with previous reports of age-dependent, mutation-dependent
deterioration of motor performance in TDP-43Q331Klow and TDP-43G348C mutant mice (Arnold et
al., 2013a; Swarup et al., 2011). Specifically, Arnold et al. (2013a) demonstrated that TDP43Q331Klow mutant mice have normal motor performance at 3- and 6-months of age, as indicated
by accelerating rotarod analyses (Arnold et al., 2013a). Re-evaluation of TDP-43Q331Klow mutant
mice at 10-months of age revealed significant motor performance deficits on the accelerating
rotarod (Arnold et al., 2013a). Arnold et al. (2013a) also evaluated the TDP-43Q331K variant,
which has higher transgene expression (3-fold) than the TDP-43Q331Klow mice, and found that
TDP-43Q331K mice displayed progressively worsening age-dependent motor performance deficits
at 3-, 6-, and 10-months of age. Further, these motor impairments were exacerbated compared to
TDP-43Q331Klow mutant mice (Arnold et al., 2013a). To summarize, TDP-43Q331Klow exhibited
moderate TDP-43 overexpression and a mild, progressive deterioration of motor performance,
consistent with previous reports using other mouse models.
Swarup et al. (2011) also demonstrated that TDP-43G348C mutant mice have normal motor
performance at 3- and 6-months of age revealed by accelerating rotarod analyses. They then reevaluated the TDP-43G348C mutant mice and found that at 9-months of age these mice exhibit
significantly reduced motor performance in an age-dependent manner (Swarup et al., 2011). This
result provides additional support for our findings of age-dependent deterioration of motor
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performance in both the TDP-43Q331Klow and TDP-43G348C mutant mice. Additionally, both the
Cleveland and Julien groups reported progressive motor degeneration without extreme muscle
weakness, spasticity or paralysis during characterization of both the TDP-43Q331Klow and TDP43G348C mutant mice (Arnold et al., 2013a; Swarup et al., 2011). This characteristic did not differ
in the TDP-43Q331Klow and TDP-43G348C mutant mice used for this investigation. Lastly, and
perhaps most importantly, during this investigation the onset of motor performance
deteriorations in TDP-43Q331Klow and TDP-43G348C mutant mice did not precede the detection
cognitive dysfunction in these mutant mouse lines (see below).

4.2 5-CSRTT Reveals Possible BPSD-like Behaviours in TDP-43 Mutant Mice
5-CSRTT acquisition (4s & 2s) phases revealed no significant differences among TDP-43Q331Klow
and TDP-43G348C mutant mice and their littermate controls, suggestive of a similar ability to
acquire the task during these two relatively lenient training phases. Furthermore, during probe
trials the TDP-43Q331Klow and TDP-43G348C mutant mice did not demonstrate any impairments in
accuracy during any time point. In fact, it appears that the accuracy of TDP-43Q331Klow mutants
were improved in this task, consistent with the very significantly increased accuracy observed in
these mutants during the 4- and 8-month timepoints. TDP-43G348C mutant mice did not show any
evidence of improvement.
4-month-old TDP-43Q331Klow mutants did, however, demonstrate evidence of early increased
perseverative responses. Early perseverative behaviour is one of the first and most prominent
BPSD symptoms in human FTD (Erkkinen et al., 2018; Tible et al., 2017; Young et al., 2018).
Recently, the Q331K mutation was humanized in mice, generating a novel TDP-43Q331K KI
mouse model (White et al., 2018), and reversal learning impairments driven by stimulus-bound
perseverative responding have been reported in these mice (Kim et al., 2020). Between these two
investigations it is evident that TDP-43Q331K(low/KI) may in fact share a perseverative response
phenotype. Additionally, because cognitive impairment is often reported before motor
dysfunction in human FTD/ALS cases (Elamin et al., 2011; Giordana et al., 2011), the TDP43Q331Klow mutant mouse model may be ideal for evaluations of early perseveration preceding
the development of motor dysfunction in mice.
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It was also found that the TDP-43Q331Klow mutants exhibited significantly increased omissions
during the 4- and 8-month time points. The TDP-43G348C mutants also exhibited a significant
increase in omissions; however, this increase was constrained to the 8-month time point. These
observed increases in omissions by TDP-43 mutants highlight the possibility of a decreased
capacity to maintain prolonged attentional focus in these mice. Alternatively, failure to respond
to targets may evidence an increase in apathetic behaviour in the TDP-43Q331Klow and TDP43G348C mutants. In addition to increased omissions in the 5-CSRTT, TDP-43Q331Klow mutant
mice showed longer latencies (reward collection, correct touch, and incorrect touch) in the PVD
task (4-months old). This was in the face of intact locomotor performance and no evidence of
hyper- or hypo- activity. Thus, we sought to test motivation/apathy in these animals directly.

4.3 Limited Evidence for Motivational impairments in TDP-43Q331Klow and TDP-43G348C
mutant mice
To further explore motivation/apathy concerns raised during the 5-CSRTT, the PRFR task
(which evaluates motivation) was used to identify whether TDP-43 mutant mice exhibit
apathetic-like behaviours or have decreased motivation. However, the PRFR task did not reveal
any motivation-based deficits in TDP-43G348C mutant mice. The TDP-43Q331Klow mutants, in
contrast, were slower to collect rewards (FR3 schedule only), yet following reward collection
initiated subsequent trials significantly faster as revealed by the post reinforcement pause
measures (PR12 schedule only). This finding taken alone could suggest an increase in
motivation. However, motivation measured by breakpoints was normal. Thus, there is not strong
evidence to suggest that the TDP-43Q331Klow mutants are more or less motivated than controls.
As TDP-43Q331Klow mice exhibited evidence of perseveration, it is conceivable that perseverative
responding may have increased breakpoint, thus masking a motivational impairment. Kim et al.
(2020) assessed this possibility in their TDP-43Q331K KI mice using rate analysis of PRFR. These
authors found that the TDP-43Q331K KI mice demonstrated increased responding (total responses)
during PR, but decreased rates of PR responding, in addition to increased omissions during PR
extinction (no reward). Kim et al. (2020) interpreted this pattern of results as evidence for both
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perseveration and amotivation in their mice. Unfortunately, due to constraints imposed by
COVID-19, I was unable to extract my data and perform this same analysis.

4.4 Evidence of Cognitive Flexibility Deficits in TDP-43 Mutant Mice
TDP-43Q331Klow and TDP-43G348C mutant mice exhibited significant performance deficits in the
PVD task. During the acquisition phase both TDP-43Q331Klow and TDP-43G348C mutant lines
required more sessions to acquire the task and meet performance criterion. This suggests that
learning impairments may be present in the TDP-43Q331Klow and TDP-43G348C mice. Furthermore,
TDP-43Q331Klow and TDP-43G348C mutants made significantly more errors during the reversal
learning phase, when the stimulus reward contingency is reversed. Impaired performance during
PVD reversal is indicative of compromised cognitive flexibility in the TDP-43G348C and TDP43Q331Klow mutant mice, which is a common feature of human FTD/ALS (Erkkinen et al., 2018;
Kawakami et al., 2019; Tible et al., 2017; Young et al., 2018). Indeed, the orbitofrontal cortex
characteristically displays early progressive degeneration followed by the dorsolateral prefrontal
cortex in human FTD/ALS. Learning and cognitive flexibility deficits are primarily affected by
the degeneration of these regions (Erkkinen et al., 2018; Evans et al., 2015; Kawakami et al.,
2019; Young et al., 2018).

Impairments in reversal learning can be separated into early-stage performance deficits and latestage performance deficits. Early-stage performance impairments (accuracy ≤50%) is driven by
perseverative behaviour. Whereas late stage performance (accuracy ≥50%) is driven by learning
the new stimulus-reward contingency (Graybeal et al., 2011). The deficits exhibited by TDP43Q331Klow mutant mice during the reversal phase appear to manifest as early as the second
session and persist throughout the majority of sessions. This suggests that these mice are
impaired early in reversal (≤ 50%), consistent with a perseveration-induced impairment. Once
TDP-43Q331Klow mutants progressed into late-stage performance (≥50%), performance deficits
may still be driven by perseveration, but to a lesser degree. It must be noted, however, that TDP43G348C mice also demonstrated reduced performance in initial acquisition of the PVD task, and
so both acquisition and reversal deficits could be indicative of a generalised learning impairment.
Indeed, the TDP-43G348C mutant mice did not exhibit a perseverative response phenotype in the
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5-CSRTT task. In contrast, however, the TDP-43Q331Klow mutants exhibited an early
perseverative response phenotype at an identical time point of 4-months in the 5-CSRTT.
Finally, the idea that these mice exhibit a generalised learning impairment is virtually ruled out
by the observation that both TDP-43Q331Klow and TDP-43G348C mutant mouse lines exhibited
intact performance in the much more difficult dPAL task (discussed below). Thus, we interpret
the reversal learning impairments seen in this study as likely driven by perseveration.
Our lab, when operating at University Cambridge investigated the TDP-43Q331K KI model using
the same PVD (visual discrimination/reversal learning; VDR) task used here (Kim et al., 2020).
The TDP-43Q331K KI mice demonstrated task acquisition impairments in a manner similar to the
TDP-43Q331Klow mutants here (Kim et al., 2020). Furthermore, they revealed a very similar
pattern cognitive inflexibility in their TDP-43Q331K KI model. Specifically, their data indicate
that the TDP-43Q331K KIs exhibit stimulus-bound, perseveration-related reversal learning deficits
(Kim et al., 2020), similar to mice in the present study. Both TDP-43Q331K(low/KI) mutant
variants present with similar pathology to the TDP-43Q331K KI model in that they lack TDP-43
mislocalization and aggregation (White et al., 2018). Additionally, at least in the TDP-43Q331Klow
transgenic mice, the deficits precede the development of motor impairment (TDP Q331K KI lack
motor dysfunction; Kim et al., 2020; White et al., 2018). This provides further evidence that
TDP-43 neurodegeneration and cognitive dysfunction in mice can occur in the absence of
mislocalization and aggregation.

4.5 TDP-43 Mutant Mice Do Not Exhibit Any Apparent Deficits in the dPAL Task
Both TDP-43Q331Klow and TDP-43G348C mutant mouse lines exhibited highly consistent
visuospatial memory performance in the dPAL task, with neither mutant line showing any
significant visuospatial impairments. Both TDP-43Q331Klow and TDP-43G348C mutant mouse lines
were able to achieve ~80% accuracy by task completion, which is the normative performance
ceiling of mice in the dPAL task. This finding was largely expected due to the relatively spared
visuospatial performance observed in human FTD/ALS pathology (Erkkinen et al., 2018;
Kawakami et al., 2019). This is consistent with the observation that in FTD/ALS the
hippocampus, perirhinal cortex, parahippocampal cortex and visual cortex -- areas important for
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visuospatial learning -- degenerate only in the latest and most severe stages of FTD/ALS
(Kawakami et al., 2019).

4.6 Investigation Limitations
This investigation, although informative, has a few limitations. The first was the use of only male
mice. The importance of understanding the dynamics of neurodegenerative diseases such as
FTD/ALS within the context of both male and female sexes is necessary, and future experiments
should include both sexes. For this preliminary study, however, males were chosen as males are
more affected by ALS, with higher risk for the disease compared to females (Longinetti & Fang,
2019).

Secondly, there is some variability present in the reward collection-, correct touch-, incorrect
touch- and perseverative response latency data of both TDP-43Q331Klow and TDP-43G348C mutant
lines. Among the mutants exhibiting the highest variability, it is possible that these same mutants
experience the earliest and perhaps most severe impairment. However, this is merely speculatory
and requires subsequent analysis for a conclusive determination. Certainly, it would also be
interesting to observe the severity of TDP-43 pathology in these mice for the possibility of
deficits corresponding with pathological TDP-43 progression. With respect to the 5-CSRTT,
only a single cohort of TDP-43G348C mutants were examined. It is likely that the variation
observed throughout these experiments would have been reduced by the higher n values
originally planned. Unfortunately, due to the global pandemic ceasing experiments, issues
concerning variability could not be further investigated.
Lastly, biochemical and histopathological confirmation of TDP-43 pathology in TDP-43Q331Klow
and TDP-43G348C mutants unfortunately was not completed. The global pandemic created
unforeseen circumstances, and brain and spinal tissue sample analysis was no longer possible.
However, both TDP-43 Q331Klow the and TDP-43G348C transgenic mouse models of FTD/ALS
have been extensively described previously by the Cleveland and Julien groups respectively
(Arnold et al., 2013a, 2013b; Swarup et al., 2011), and our mice are likely similar.
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4.7 Future Directions – Can Cognitive Deficits be Linked to Specific Pathological TDP-43
Events?
The results of this investigation provide some exciting insights into early cognitive deficits in
FTD/ALS mutant mouse models. However, there is another limitation to this investigation that
can be improved by future investigations; namely, the omission of an overexpressing WT-TDP43 mouse line. This omission makes it difficult to assess the relative contribution of
overexpression in TDP-43 pathology-related cognitive deficits. This limitation is worsened by
the lack of a mutant TDP-43 line without overexpression (knock-in). The combination of these
two limitations removes the capacity to effectively delineate whether cognitive deficits result
from TDP-43 mutations or overexpression. However, the robust and highly similar TDP43Q331K(low/KI) data presented here and in a separate investigation using a KI model (Kim et al.
2020) suggest that overexpression may not be required for neurodegeneration and/or cognitive
dysfunction.

Recently it has also been suggested that pathological TDP-43 aggregates may actually represent
a penultimate or final stage of FTD/ALS pathology, where relevant cellular machinery has
already been overwhelmed and is incapable of preventing or reversing TDP-43 phase transitions
(J. R. Mann et al., 2019). It should be possible to investigate cognitive alterations resulting from
phase transitions in TDP-43Q331K KI (no overexpression), TDP-43Q331Klow (0.5-fold increase) and
TDP-43G348C or Q331K (3-fold increase with TDP-43 aggregation) mice using automated
touchscreens. We have already shown here cognitive deficits in 4-month-old (TDP-43G348C and
TDP-43Q331Klow) mice preceding late-stage ALS phenotypes (TDP-43 mislocalization,
aggregation and motor dysfunction; Arnold et al., 2013a; Swarup et al., 2011). Additionally,
because TDP-43G348C pathological aggregation and ubiquitination progressively worsens over
time (e.g., 6mo, 10mo), in such a study cognitive deficits could be correlated with TDP-43
pathology (Swarup et al., 2011).

An optogenetic approach could be the most informative method for investigating cognitive
dysfunction preceding aggregation in the TDP-43 mouse lines. A Cry2 (blue-light receptor) has
been used previously in human cell lines and zebrafish investigations to drive TDP-43
oligomerization and phase transitions (Asakawa et al., 2020; J. R. Mann et al., 2019; Shin et al.,
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2017). Further, the Asakawa group developed an optogenetic oligomerization construct by using
a point mutation (E490G) to modify zebrafish Cry2, and then fuse Cry2 to the c-terminal (prionlike low-complexity domain) of TDP-43A315T (tdp43-Cry2-olig). Blue-light stimulation of the
tdp43-Cry2-olig construct triggers substantial clustering under exposure to blue light (Asakawa
et al., 2020). Spatiotemporal control of TDP-43Q331K(low/KI) and TDP-43G348C oligomerization
and phase transitions could facilitate investigation of upstream TDP-43 mechanisms by
correlating cognitive dysfunction with the presence or absence of pathological events (e.g.,
mislocalization, aggregation, SG recruitment). This could prove to be extremely informative in
determining the pathomechanism(s) or event(s) which result in FTD/ALS cognitive dysfunction
and motor degeneration. At the time of writing, automated touchscreen systems are already
capable of evaluating mice using integrated optogenetic equipment, and inciting TDP-43
oligomerization and phase transitions in mice should be feasible with the development of a Cry2oligomerization construct in TDP-43 mice (Asakawa et al., 2020; Dumont et al., 2020; J. R.
Mann et al., 2019; Shin et al., 2017). Certainly, adopting this approach may prove useful in
addressing the limitations of this study and provide a more comprehensive understanding of
human FTD/ALS pathomechanisms and cognitive aspects.

4.8 Final Conclusions
We explored the possibility of huTDP-43 transgene (G348C & Q331K)-mediated early cognitive
deficits in mouse models of FTD/ALS. We demonstrated that human ALS-linked TDP43Q331Klow and TDP-43G348C mutant mouse models exhibit highly similar cognitive changes,
revealed by automated touchscreens with validated tasks. The cognitive flexibility deficits
revealed by the PVD task, and exhibited in both the TDP-43Q331Klow and TDP-43G348C mouse
lines, recapitulates principal features of BPSD (dysexecutive function and perseveration) in
human FTD/ALS (Erkkinen et al., 2018; Tible et al., 2017; Young et al., 2018). A potential early
perseverative response phenotype was also revealed in the TDP-43Q331Klow mutant mouse line
across two unique touchscreen tasks (5-CSRTT & PVD). Both of these findings are similar to
those reported by another study using a knock-in model, providing additional evidence in support
of the findings presented here (Kim et al., 2020). Furthermore, these deficits of executive
function precede FTD/ALS-induced motor impairments in TDP-43 mutant mice. Collectively,
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these results highlight that the combination of TDP-43 mouse models and touchscreen tests may
potentially be useful tools for understanding and developing FTD/ALS cognitive therapies.
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